<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sci Rep</journal-id><journal-id journal-id-type="iso-abbrev">Sci Rep</journal-id><journal-id journal-id-type="pmc-domain-id">1579</journal-id><journal-id journal-id-type="pmc-domain">scirep</journal-id><journal-title-group><journal-title>Scientific Reports</journal-title></journal-title-group><issn pub-type="epub">2045-2322</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12134259</article-id><article-id pub-id-type="pmcid-ver">PMC12134259.1</article-id><article-id pub-id-type="pmcaid">12134259</article-id><article-id pub-id-type="pmcaiid">12134259</article-id><article-id pub-id-type="pmid">40461596</article-id><article-id pub-id-type="doi">10.1038/s41598-025-03797-9</article-id><article-id pub-id-type="publisher-id">3797</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Factors associated with severe lower extremity artery disease in type 2 diabetes based on a large scale claims database in Japan</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Horii</surname><given-names initials="T">Takeshi</given-names></name><address><email>t-horii@musashino-u.ac.jp</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kawaguchi</surname><given-names initials="M">Marina</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ikegami</surname><given-names initials="Y">Yuichi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Oikawa</surname><given-names initials="Y">Yoichi</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Shimada</surname><given-names initials="A">Akira</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mihara</surname><given-names initials="K">Kiyoshi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04bcbax71</institution-id><institution-id institution-id-type="GRID">grid.411867.d</institution-id><institution-id institution-id-type="ISNI">0000 0001 0356 8417</institution-id><institution>Department of Pharmacy, Faculty of Pharmacy, </institution><institution>Musashino University, </institution></institution-wrap>Tokyo, Japan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04zb31v77</institution-id><institution-id institution-id-type="GRID">grid.410802.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2216 2631</institution-id><institution>Department of Endocrinology and Diabetes, School of Medicine, </institution><institution>Saitama Medical University, </institution></institution-wrap>Saitama, Japan </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>6</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>15</volume><issue-id pub-id-type="pmc-issue-id">478255</issue-id><elocation-id>19358</elocation-id><history><date date-type="received"><day>28</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>22</day><month>5</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>06</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-05 11:25:42.047"><day>05</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41598_2025_Article_3797.pdf"/><abstract id="Abs1"><p id="Par1">Diabetic foot lesions are becoming increasingly prevalent due to increases in type 2 diabetes (T2D), aging populations, and atherosclerotic diseases. Individuals with T2D with comorbid lower extremity artery disease (LEAD) are particularly susceptible. Although pharmacological therapies are often combined with risk management strategies, like exercise and smoking cessation, their roles in preventing LEAD progression are unclear. Herein, we investigated factors suppressing LEAD progression in T2D. Using data from the DeSC database, this retrospective cross-sectional study defined severe LEAD as a diagnosis requiring revascularization (Revasc). Logistic regression analysis was used to calculate odds ratios (ORs) for associated factors. The analysis included 243,606 patients with T2D divided into two groups; those with (<italic toggle="yes">n</italic>&#8201;=&#8201;890) and without (<italic toggle="yes">n</italic>&#8201;=&#8201;242,716) Revasc. Subgroup analysis of patients with LEAD (<italic toggle="yes">n</italic>&#8201;=&#8201;27,258) with (<italic toggle="yes">n</italic>&#8201;=&#8201;890) and without (<italic toggle="yes">n</italic>&#8201;=&#8201;26,368) Revasc was also conducted. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) (OR 0.50), metformin (OR 0.78), and fibrates (OR 0.75) were associated with a significant reduction in severe LEAD in the primary and subgroup analyses. In conclusion, the active use of SGLT2 inhibitors, metformin, and fibrates may help prevent LEAD progression. However, these medications are associated with adverse events, making it essential to manage patients individually to optimize benefits while minimizing risks.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1038/s41598-025-03797-9.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetic foot lesions</kwd><kwd>Type 2 diabetes</kwd><kwd>Lower extremity artery disease</kwd><kwd>Revascularization</kwd></kwd-group><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Endocrinology</kwd><kwd>Endocrine system and metabolic diseases</kwd><kwd>Diabetes</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100019640</institution-id><institution>Musashino University</institution></institution-wrap></funding-source><award-id>O6-172</award-id><principal-award-recipient><name name-style="western"><surname>Horii</surname><given-names>Takeshi</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Limited 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Type 2 diabetes (T2D) is associated with both microvascular and macrovascular complications due to persistent hyperglycemia<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup> Among these, diabetic foot lesions have become increasingly prevalent due to the increase in T2D incidence, aging populations, and atherosclerotic diseases. Individuals with T2D are particularly susceptible to developing foot lesions when they have comorbid lower extremity artery disease (LEAD)<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>. Systematic reviews<sup><xref ref-type="bibr" rid="CR5">5</xref></sup> on LEAD have identified diabetes as a significant risk factor for its onset. According to a survey by Japan&#8217;s Ministry of Health, Labour and Welfare, 0.7% of patients with diabetes have foot gangrene<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Internationally, the prevalence of diabetic foot ulcers ranges from 1.5 to 10%, with an incidence of 2.2&#8211;5.9%<sup><xref ref-type="bibr" rid="CR7">7</xref>&#8211;<xref ref-type="bibr" rid="CR9">9</xref></sup>. Meta-analyses<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> in Japan have demonstrated that diabetes impacts LEAD more significantly than coronary artery disease (CAD). In a study focusing on patients with T2D with a mean age of 61 years, the prevalence of an ankle-brachial index (ABI) below 0.90 was reported to be 7.0%. Among patients aged 65 years or older, this prevalence increased to 12.7%<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. Moreover, patients with T2D and an ABI between 0.90 and 1.00 exhibit a high risk of progressing to LEAD, necessitating careful longitudinal monitoring<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Hypertension and dyslipidemia, common risk factors for T2D, are also shared risk factors for LEAD. The overlapping of these risk factors results in a 1.5- to 10-fold increase in the incidence of LEAD<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Additionally, LEAD frequently coexists with other atherosclerotic conditions, such as CAD and cerebrovascular disease (CVD), with adjusted analyses indicating a 1.5- to 2-fold higher risk of cardiovascular events in patients with LEAD<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>.</p><p id="Par3">The treatment strategy for LEAD varies significantly depending on the severity of symptoms and degree of ischemia. In cases of chronic limb-threatening ischemia (CLTI), characterized by infection or critical ischemia, surgical interventions such as debridement, minor amputations, or revascularization (Revasc) procedures are frequently necessitated. The risk of symptom recurrence within 3 years following Revasc has been reported to be 30% for bypass surgery and 64% for endovascular therapy (EVT)<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Regarding prognosis, cumulative mortality rates post-Revasc are approximately between 10% and 15% at 3 years<sup><xref ref-type="bibr" rid="CR15">15</xref>&#8211;<xref ref-type="bibr" rid="CR17">17</xref></sup>, while the 5-year mortality following EVT approaches 20%<sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref></sup>. In advanced cases, major amputations aimed at alleviating ischemic pain and removing necrotic or infected tissues become necessary. Although efficacious, major amputations significantly impact patients&#8217; quality of life. Moreover, additional procedures, including debridement or re-amputation, are required in 4&#8211;40% of cases depending on the level of amputation<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>.</p><p id="Par4">Rehospitalization rates following toe or foot amputations are approximately 20%, with the majority occurring within the first month<sup><xref ref-type="bibr" rid="CR20">20</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref></sup>. The prognosis following major amputations in patients with diabetes and CLTI is less favorable than that in non-diabetic patients, with the cumulative survival rates at 1, 3, 5, and 10 years reported to be 78%, 61%, 44%, and 19%, respectively<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>. Comprehensive risk factor management is essential not only for preventing the onset and progression of LEAD, but also for improving patient outcomes. Despite this, LEAD is often underdiagnosed in clinical practice, and even when diagnosed, is frequently inadequately managed<sup><xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref></sup>. While pharmacological therapies are frequently combined with comprehensive risk management strategies, such as exercise and smoking cessation, there is a paucity of reports that adequately examine the contribution of these interventions in preventing the progression of LEAD.</p><p id="Par5">Given that patients with advanced LEAD and type 2 diabetes (T2D) often present with multiple comorbidities, a comprehensive evaluation of concomitant medications and comorbid conditions is necessary to assess their potential impact. To address this knowledge gap, we conducted a large-scale retrospective cross-sectional study utilizing a healthcare claims database encompassing the working-age population in Japan, with the aim of investigating factors inhibiting the progression of LEAD in patients with T2D.</p></sec><sec id="Sec2"><title>Results</title><p id="Par6">Table&#160;<xref rid="Tab1" ref-type="table">1</xref> shows baseline patient characteristics. The mean age was 61.9&#8201;&#177;&#8201;8.4 years, with a nearly equal distribution of men and women. Approximately 3% of patients were classified as underweight (BMI&#8201;&lt;&#8201;18.5&#160;kg/m&#178;). Revasc was confirmed in 890 of 243,606 patients (0.37%). There were significant differences in many clinical parameters between the Revasc (+) and Revasc (&#8722;) groups. Compared with the Revasc (-) group, the Revasc (+) group had a larger proportion of men, were older, and had a lower BMI. The frequency of complications and concomitant medication use in each group are shown in Table&#160;<xref rid="Tab1" ref-type="table">1</xref>.</p><p id="Par7">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Baseline characteristics of patients with type 2 diabetes classified by the presence or absence of revascularization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">Overall (<italic toggle="yes">n</italic>&#8201;=&#8201;243,606)</th><th align="left" colspan="1" rowspan="1">Revasc (&#8722;) groups (<italic toggle="yes">n</italic>&#8201;=&#8201;242,716)</th><th align="left" colspan="1" rowspan="1">Revasc (+) groups (<italic toggle="yes">n</italic>&#8201;=&#8201;890)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex, n (%)</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">139,525 (57.3)</td><td align="left" colspan="1" rowspan="1">138,787 (57.2)</td><td align="left" colspan="1" rowspan="1">738 (82.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">104,081 (42.7)</td><td align="left" colspan="1" rowspan="1">103,929 (42.8)</td><td align="left" colspan="1" rowspan="1">152 (17.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">Mean (years)</td><td align="left" colspan="1" rowspan="1">61.9&#8201;&#177;&#8201;8.4</td><td align="left" colspan="1" rowspan="1">61.8&#8201;&#177;&#8201;8.4</td><td align="left" colspan="1" rowspan="1">64.3&#8201;&#177;&#8201;0.5</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td align="left" colspan="1" rowspan="1">Mean (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">25.2&#8201;&#177;&#8201;4.2</td><td align="left" colspan="1" rowspan="1">25.2&#8201;&#177;&#8201;4.2</td><td align="left" colspan="1" rowspan="1">24.3&#8201;&#177;&#8201;3.7</td><td char="." align="char" colspan="1" rowspan="1">0.028</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">236,616 (97.1)</td><td align="left" colspan="1" rowspan="1">235,761 (97.1)</td><td align="left" colspan="1" rowspan="1">855 (96.1)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">6990 (2.9)</td><td align="left" colspan="1" rowspan="1">6955 (2.9)</td><td align="left" colspan="1" rowspan="1">35 (3.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">HbA1c</td><td align="left" colspan="1" rowspan="1">Mean (%)</td><td align="left" colspan="1" rowspan="1">6.7&#8201;&#177;&#8201;1.4</td><td align="left" colspan="1" rowspan="1">6.7&#8201;&#177;&#8201;1.4</td><td align="left" colspan="1" rowspan="1">7.0&#8201;&#177;&#8201;1.6</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">78,733 (32.3)</td><td align="left" colspan="1" rowspan="1">78,369 (32.3)</td><td align="left" colspan="1" rowspan="1">364 (40.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">164,873 (67.7)</td><td align="left" colspan="1" rowspan="1">164,347 (67.7)</td><td align="left" colspan="1" rowspan="1">526 (59.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR</td><td align="left" colspan="1" rowspan="1">Mean (mL/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">74.0&#8201;&#177;&#8201;17.8</td><td align="left" colspan="1" rowspan="1">74.0&#8201;&#177;&#8201;17.8</td><td align="left" colspan="1" rowspan="1">63.9&#8201;&#177;&#8201;23.6</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">198,716 (81.6)</td><td align="left" colspan="1" rowspan="1">198,161 (81.6)</td><td align="left" colspan="1" rowspan="1">555 (62.4)</td><td char="." align="char" rowspan="3" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30 to &lt;60</td><td align="left" colspan="1" rowspan="1">42,917 (17.6)</td><td align="left" colspan="1" rowspan="1">42,657 (17.6)</td><td align="left" colspan="1" rowspan="1">260 (29.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">1973 (0.8)</td><td align="left" colspan="1" rowspan="1">1898 (0.8)</td><td align="left" colspan="1" rowspan="1">75 (8.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure</td><td align="left" colspan="1" rowspan="1">Mean (mmHg)</td><td align="left" colspan="1" rowspan="1">82.2&#8201;&#177;&#8201;11.9</td><td align="left" colspan="1" rowspan="1">82.2&#8201;&#177;&#8201;11.9</td><td align="left" colspan="1" rowspan="1">81.0&#8201;&#177;&#8201;12.4</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;80</td><td align="left" colspan="1" rowspan="1">145,544 (59.7)</td><td align="left" colspan="1" rowspan="1">145,069 (59.8)</td><td align="left" colspan="1" rowspan="1">475 (53.4)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;80</td><td align="left" colspan="1" rowspan="1">98,062 (40.3)</td><td align="left" colspan="1" rowspan="1">97,647 (40.2)</td><td align="left" colspan="1" rowspan="1">415 (46.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure</td><td align="left" colspan="1" rowspan="1">Mean (mmHg)</td><td align="left" colspan="1" rowspan="1">139.7&#8201;&#177;&#8201;17.9</td><td align="left" colspan="1" rowspan="1">149.7&#8201;&#177;&#8201;17.8</td><td align="left" colspan="1" rowspan="1">145.8&#8201;&#177;&#8201;20.3</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;130</td><td align="left" colspan="1" rowspan="1">175,913 (72.2)</td><td align="left" colspan="1" rowspan="1">175,210 (72.2)</td><td align="left" colspan="1" rowspan="1">703 (79.0)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;130</td><td align="left" colspan="1" rowspan="1">67,693 (27.8)</td><td align="left" colspan="1" rowspan="1">67,506 (27.8)</td><td align="left" colspan="1" rowspan="1">187 (21.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL-C</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">64.0&#8201;&#177;&#8201;17.8</td><td align="left" colspan="1" rowspan="1">64.0&#8201;&#177;&#8201;17.8</td><td align="left" colspan="1" rowspan="1">59.4&#8201;&#177;&#8201;17.2</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;40</td><td align="left" colspan="1" rowspan="1">13,057 (5.4)</td><td align="left" colspan="1" rowspan="1">12,966 (5.3)</td><td align="left" colspan="1" rowspan="1">91 (10.2)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;40</td><td align="left" colspan="1" rowspan="1">230,549 (94.6)</td><td align="left" colspan="1" rowspan="1">229,750 (94.7)</td><td align="left" colspan="1" rowspan="1">799 (89.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">131.0&#8201;&#177;&#8201;34.7</td><td align="left" colspan="1" rowspan="1">131.0&#8201;&#177;&#8201;34.7</td><td align="left" colspan="1" rowspan="1">122.3&#8201;&#177;&#8201;38.8</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;120</td><td align="left" colspan="1" rowspan="1">149,354 (61.3)</td><td align="left" colspan="1" rowspan="1">148,901 (61.3)</td><td align="left" colspan="1" rowspan="1">453 (50.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;120</td><td align="left" colspan="1" rowspan="1">94,252 (38.7)</td><td align="left" colspan="1" rowspan="1">93,815 (38.7)</td><td align="left" colspan="1" rowspan="1">437 (49.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">TG</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">177.9&#8201;&#177;&#8201;145.8</td><td align="left" colspan="1" rowspan="1">177.8&#8201;&#177;&#8201;145.7</td><td align="left" colspan="1" rowspan="1">200.6&#8201;&#177;&#8201;171.2</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;150</td><td align="left" colspan="1" rowspan="1">114,646 (47.1)</td><td align="left" colspan="1" rowspan="1">114,172 (47.0)</td><td align="left" colspan="1" rowspan="1">474 (53.3)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;150</td><td align="left" colspan="1" rowspan="1">128,960 (52.9)</td><td align="left" colspan="1" rowspan="1">128,544 (53.0)</td><td align="left" colspan="1" rowspan="1">416 (46.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking history</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">208,807 (85.7)</td><td align="left" colspan="1" rowspan="1">208,170 (85.8)</td><td align="left" colspan="1" rowspan="1">637 (71.6)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">34,799 (14.3)</td><td align="left" colspan="1" rowspan="1">34,546 (14.2)</td><td align="left" colspan="1" rowspan="1">253 (28.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Drinking history</td><td align="left" colspan="1" rowspan="1">Every day</td><td align="left" colspan="1" rowspan="1">45,174 (18.5)</td><td align="left" colspan="1" rowspan="1">44,950 (18.5)</td><td align="left" colspan="1" rowspan="1">224 (25.1)</td><td char="." align="char" rowspan="4" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sometimes</td><td align="left" colspan="1" rowspan="1">46,954 (19.3)</td><td align="left" colspan="1" rowspan="1">46,782 (19.3)</td><td align="left" colspan="1" rowspan="1">172 (19.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Rarely</td><td align="left" colspan="1" rowspan="1">141,484 (58.1)</td><td align="left" colspan="1" rowspan="1">141,043 (58.1)</td><td align="left" colspan="1" rowspan="1">441 (49.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">9994 (4.1)</td><td align="left" colspan="1" rowspan="1">9941 (4.1)</td><td align="left" colspan="1" rowspan="1">53 (6.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Complication</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Angina</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">51,079 (21.0)</td><td align="left" colspan="1" rowspan="1">50,594 (20.8)</td><td align="left" colspan="1" rowspan="1">485 (54.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Arrhythmia</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">45,369 (18.6)</td><td align="left" colspan="1" rowspan="1">45,047 (18.6)</td><td align="left" colspan="1" rowspan="1">322 (36.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cerebral infraction</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">46,850 (19.2)</td><td align="left" colspan="1" rowspan="1">46,196 (19.0)</td><td align="left" colspan="1" rowspan="1">654 (73.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">16,821 (6.9)</td><td align="left" colspan="1" rowspan="1">16,604 (6.8)</td><td align="left" colspan="1" rowspan="1">217 (24.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart failure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">58,184 (23.9)</td><td align="left" colspan="1" rowspan="1">57,644 (23.7)</td><td align="left" colspan="1" rowspan="1">540 (60.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">111,995 (46.0)</td><td align="left" colspan="1" rowspan="1">111,363 (45.9)</td><td align="left" colspan="1" rowspan="1">632 (71.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">172,677 (70.9)</td><td align="left" colspan="1" rowspan="1">171,839 (70.8)</td><td align="left" colspan="1" rowspan="1">838 (94.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Myocardial infraction</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12,215 (5.0)</td><td align="left" colspan="1" rowspan="1">1017 (0.4)</td><td align="left" colspan="1" rowspan="1">204 (22.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Neuropathy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">84,930 (34.9)</td><td align="left" colspan="1" rowspan="1">84,465 (34.8)</td><td align="left" colspan="1" rowspan="1">465 (52.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Retinopathy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">62,077 (25.5)</td><td align="left" colspan="1" rowspan="1">61,713 (25.4)</td><td align="left" colspan="1" rowspan="1">364 (40.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-diabetic agent use</td><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DPP-4is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">100,596 (41.3)</td><td align="left" colspan="1" rowspan="1">100,146 (41.3)</td><td align="left" colspan="1" rowspan="1">450 (50.6)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Glinides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13,674 (5.6)</td><td align="left" colspan="1" rowspan="1">13,595 (5.6)</td><td align="left" colspan="1" rowspan="1">79 (8.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 receptor agonists</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11,140 (4.6)</td><td align="left" colspan="1" rowspan="1">11,092 (4.6)</td><td align="left" colspan="1" rowspan="1">48 (5.4)</td><td char="." align="char" colspan="1" rowspan="1">0.241</td></tr><tr><td align="left" colspan="1" rowspan="1">Imeglimin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1658 (0.7)</td><td align="left" colspan="1" rowspan="1">1655 (0.7)</td><td align="left" colspan="1" rowspan="1">3 (0.3)</td><td char="." align="char" colspan="1" rowspan="1">0.212</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">35,343 (14.5)</td><td align="left" colspan="1" rowspan="1">35,036 (14.4)</td><td align="left" colspan="1" rowspan="1">307 (34.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">74,907 (30.7)</td><td align="left" colspan="1" rowspan="1">74,633 (30.7)</td><td align="left" colspan="1" rowspan="1">274 (30.8)</td><td char="." align="char" colspan="1" rowspan="1">0.981</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">58,077 (23.8)</td><td align="left" colspan="1" rowspan="1">57,888 (23.9)</td><td align="left" colspan="1" rowspan="1">189 (21.2)</td><td char="." align="char" colspan="1" rowspan="1">0.068</td></tr><tr><td align="left" colspan="1" rowspan="1">Sulfonylureas</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30,071 (12.3)</td><td align="left" colspan="1" rowspan="1">29,896 (12.3)</td><td align="left" colspan="1" rowspan="1">175 (19.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazolidinediones</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">16,575 (6.8)</td><td align="left" colspan="1" rowspan="1">16,501 (6.8)</td><td align="left" colspan="1" rowspan="1">74 (8.3)</td><td char="." align="char" colspan="1" rowspan="1">0.073</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-GIs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">25,175 (10.3)</td><td align="left" colspan="1" rowspan="1">25,030 (10.3)</td><td align="left" colspan="1" rowspan="1">145 (16.3)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiplatelet drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30,570 (12.5)</td><td align="left" colspan="1" rowspan="1">30,121 (12.4)</td><td align="left" colspan="1" rowspan="1">449 (50.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">P2Y12is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">19,699 (8.1)</td><td align="left" colspan="1" rowspan="1">19,307 (8.0)</td><td align="left" colspan="1" rowspan="1">392 (44.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PDEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6194 (2.5)</td><td align="left" colspan="1" rowspan="1">5929 (2.4)</td><td align="left" colspan="1" rowspan="1">265 (29.8)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antihypertensive drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ACEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13,381 (5.5)</td><td align="left" colspan="1" rowspan="1">13,274 (5.5)</td><td align="left" colspan="1" rowspan="1">107 (12.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Aldosterone receptor blocker</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12,658 (5.2)</td><td align="left" colspan="1" rowspan="1">12,518 (5.2)</td><td align="left" colspan="1" rowspan="1">140 (15.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARBs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">110,227 (45.2)</td><td align="left" colspan="1" rowspan="1">109,581 (45.1)</td><td align="left" colspan="1" rowspan="1">646 (72.6)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARNI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3185 (1.3)</td><td align="left" colspan="1" rowspan="1">3140 (1.3)</td><td align="left" colspan="1" rowspan="1">45 (5.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium channel blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">126,088 (51.8)</td><td align="left" colspan="1" rowspan="1">125,352 (51.6)</td><td align="left" colspan="1" rowspan="1">736 (82.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Loop diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">20,370 (8.4)</td><td align="left" colspan="1" rowspan="1">20,126 (8.3)</td><td align="left" colspan="1" rowspan="1">244 (27.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazide diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">18,369 (7.5)</td><td align="left" colspan="1" rowspan="1">18,214 (7.5)</td><td align="left" colspan="1" rowspan="1">155 (17.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">V2-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2227 (0.9)</td><td align="left" colspan="1" rowspan="1">180 (0.1)</td><td align="left" colspan="1" rowspan="1">42 (4.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7442 (3.1)</td><td align="left" colspan="1" rowspan="1">7325 (3.0)</td><td align="left" colspan="1" rowspan="1">117 (13.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">45,346 (18.6)</td><td align="left" colspan="1" rowspan="1">44,888 (18.5)</td><td align="left" colspan="1" rowspan="1">458 (51.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol-lowering drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">18,286 (7.5)</td><td align="left" colspan="1" rowspan="1">18,188 (7.5)</td><td align="left" colspan="1" rowspan="1">98 (11.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Eicosapentaenoic acid</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15,019 (6.2)</td><td align="left" colspan="1" rowspan="1">14,913 (6.1)</td><td align="left" colspan="1" rowspan="1">106 (11.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">23,294 (9.6)</td><td align="left" colspan="1" rowspan="1">23,214 (9.6)</td><td align="left" colspan="1" rowspan="1">80 (9.0)</td><td char="." align="char" colspan="1" rowspan="1">0.560</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">182 (0.07)</td><td align="left" colspan="1" rowspan="1">181 (0.1)</td><td align="left" colspan="1" rowspan="1">1 (0.1)</td><td char="." align="char" colspan="1" rowspan="1">0.676</td></tr><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">123,108 (50.5)</td><td align="left" colspan="1" rowspan="1">122,546 (50.5)</td><td align="left" colspan="1" rowspan="1">562 (63.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are presented as numbers (%) or means (standard deviations). The <italic toggle="yes">P</italic> value was calculated for the differences between patients with Revasc or without Revasc.</p><p>
<italic toggle="yes"> Revasc</italic> revascularization, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">HbA1c</italic> hemoglobin A1c, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate, <italic toggle="yes">HDL-C</italic> high-density lipoprotein cholesterol, <italic toggle="yes">LDL-C</italic> low-density lipoprotein cholesterol, <italic toggle="yes">TG</italic> triglycerides, <italic toggle="yes">CKD</italic> chronic kidney disease, <italic toggle="yes">DPP-4is</italic> dipeptidyl peptidase-4 inhibitors, <italic toggle="yes">GLP-1</italic> receptor agonists, glucagon-like peptide-1, <italic toggle="yes">SGLT2is</italic> sodium-glucose cotransporter 2 inhibitors, <italic toggle="yes">&#945;-GI</italic> alpha-glucosidase inhibitor, <italic toggle="yes">PDEis</italic> phosphodiesterase inhibitors, <italic toggle="yes">ACEis</italic> angiotensin-converting enzyme inhibitors, <italic toggle="yes">ARBs</italic> angiotensin II receptor blockers, <italic toggle="yes">ARNI</italic> angiotensin receptor-neprilysin inhibitor, <italic toggle="yes">V2-Receptor blockers</italic> vasopressin V2 receptor blockers.</p></table-wrap-foot></table-wrap>
</p><p id="Par8">The risk of severe LEAD is presented in Table&#160;<xref rid="Tab2" ref-type="table">2</xref>. Compared being a man, being a woman was associated with a lower OR for severe LEAD (OR 0.50; 95% CI 0.41&#8211;0.60). The OR for severe LEAD significantly increased per 10-year increments in age (OR 1.30; 95% CI 1.16&#8211;1.47). A BMI of less than 18.5&#160;kg/m<sup>2</sup>, with a BMI of 18.5&#160;kg/m<sup>2</sup> or more as the reference, was also significantly associated with LEAD (OR 2.16; 95% CI 1.50&#8211;3.11). Moreover, an eGFR of less than 30 mL/min/1.73 m<sup>2</sup> (OR 3.39; 95% CI 2.53&#8211;4.53) and between 30 and 60 mL/min/1.73 m<sup>2</sup> (OR 1.33, 95% CI 1.14&#8211;1.55), with an eGFR of 60 mL/min/1.73 m<sup>2</sup> or more as the reference, was significantly associated with LEAD. An HbA1c level of less than 7.0%, sBP, and HDL-C level of more than 40&#160;mg/dL were associated with a significantly lower OR for severe LEAD when the target set by the guidelines was achieved. However, the OR for severe LEAD significantly increased when a dBp of less than 80&#160;mg/dL was achieved. The OR increased in the presence of smoking habits, whereas alcohol consumption showed no association. The ORs for sodium-glucose cotransporter 2 inhibitors (SGLT2is), metformin, and fibrates were significantly lower than 1. In contrast, the use of insulin, antiplatelet drugs, and certain types of antihypertensive agents significantly increased the OR. Several SGLT2is and fibrates were investigated in detail (Supplementary Table S2). Among SGLT2is, dapagliflozin demonstrated a particularly low OR; however, all agents in this class tended to lower the OR. Fibrate use was associated with lower ORs for severe LEAD. Among fibrates, pemafibrate, which exerts anti-peroxisome proliferator-activated receptor alpha (PPAR&#945;) action, was associated with lower ORs for severe LEAD. Due to the limited number of patients who received clofibrate, it was not possible to analyze its effects.</p><p id="Par9">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Logistic regression analysis of factors associated with the implementation of revascularization in patients with type 2 diabetes.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Odds ratio</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1">0.41&#8211;0.60</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Age/10years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.30</td><td align="left" colspan="1" rowspan="1">1.16&#8211;1.47</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">2.16</td><td align="left" colspan="1" rowspan="1">1.50&#8211;3.11</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">HbA1c (%)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">0.53&#8211;0.75</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR (mL/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30 to &lt;60</td><td align="left" colspan="1" rowspan="1">1.33</td><td align="left" colspan="1" rowspan="1">1.14&#8211;1.55</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">3.39</td><td align="left" colspan="1" rowspan="1">2.53&#8211;4.53</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;80</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;80</td><td align="left" colspan="1" rowspan="1">1.54</td><td align="left" colspan="1" rowspan="1">1.32&#8211;1.80</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;130</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;130</td><td align="left" colspan="1" rowspan="1">0.83</td><td align="left" colspan="1" rowspan="1">0.69&#8211;0.99</td><td char="." align="char" colspan="1" rowspan="1">0.048</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL-C (mg/dL)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;40</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;40</td><td align="left" colspan="1" rowspan="1">1.08</td><td align="left" colspan="1" rowspan="1">0.85&#8211;1.36</td><td char="." align="char" colspan="1" rowspan="1">0.549</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;120</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;120</td><td align="left" colspan="1" rowspan="1">0.95</td><td align="left" colspan="1" rowspan="1">0.83&#8211;1.10</td><td char="." align="char" colspan="1" rowspan="1">0.526</td></tr><tr><td align="left" colspan="1" rowspan="1">TG (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;150</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;150</td><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.76&#8211;1.01</td><td char="." align="char" colspan="1" rowspan="1">0.077</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking history</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">2.05</td><td align="left" colspan="1" rowspan="1">1.75&#8211;2.40</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Drinking history</td><td align="left" colspan="1" rowspan="1">Every day</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sometimes</td><td align="left" colspan="1" rowspan="1">1.05</td><td align="left" colspan="1" rowspan="1">0.85&#8211;1.29</td><td char="." align="char" colspan="1" rowspan="1">0.667</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Rarely</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.76&#8211;1.08</td><td char="." align="char" colspan="1" rowspan="1">0.268</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">1.16</td><td align="left" colspan="1" rowspan="1">0.85&#8211;1.58</td><td char="." align="char" colspan="1" rowspan="1">0.354</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-diabetic agent use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DPP-4is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.94</td><td align="left" colspan="1" rowspan="1">0.79&#8211;1.11</td><td char="." align="char" colspan="1" rowspan="1">0.445</td></tr><tr><td align="left" colspan="1" rowspan="1">Glinides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.92</td><td align="left" colspan="1" rowspan="1">0.71&#8211;1.20</td><td char="." align="char" colspan="1" rowspan="1">0.537</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 receptor agonists</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Imeglimin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.41</td><td align="left" colspan="1" rowspan="1">1.19&#8211;1.67</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.78</td><td align="left" colspan="1" rowspan="1">0.65&#8211;0.92</td><td char="." align="char" colspan="1" rowspan="1">0.005</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.50</td><td align="left" colspan="1" rowspan="1">0.41&#8211;0.60</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Sulfonylureas</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.21</td><td align="left" colspan="1" rowspan="1">0.99&#8211;1.47</td><td char="." align="char" colspan="1" rowspan="1">0.059</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazolidinediones</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.76&#8211;1.27</td><td char="." align="char" colspan="1" rowspan="1">0.903</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-GIs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.11</td><td align="left" colspan="1" rowspan="1">0.90&#8211;1.36</td><td char="." align="char" colspan="1" rowspan="1">0.332</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiplatelet drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.99</td><td align="left" colspan="1" rowspan="1">1.67&#8211;2.36</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">P2Y12is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2.66</td><td align="left" colspan="1" rowspan="1">2.24&#8211;3.15</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PDEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.15</td><td align="left" colspan="1" rowspan="1">6.11&#8211;8.38</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antihypertensive drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ACEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.83</td><td align="left" colspan="1" rowspan="1">0.67&#8211;1.04</td><td char="." align="char" colspan="1" rowspan="1">0.103</td></tr><tr><td align="left" colspan="1" rowspan="1">Aldosterone receptor blocker</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.21</td><td align="left" colspan="1" rowspan="1">0.96&#8211;1.51</td><td char="." align="char" colspan="1" rowspan="1">0.104</td></tr><tr><td align="left" colspan="1" rowspan="1">ARBs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.41</td><td align="left" colspan="1" rowspan="1">1.19&#8211;1.66</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARNI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.41</td><td align="left" colspan="1" rowspan="1">1.01&#8211;1.96</td><td char="." align="char" colspan="1" rowspan="1">0.042</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium channel blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.97</td><td align="left" colspan="1" rowspan="1">1.62&#8211;2.39</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Loop diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.29</td><td align="left" colspan="1" rowspan="1">1.06&#8211;1.57</td><td char="." align="char" colspan="1" rowspan="1">0.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazide diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.18</td><td align="left" colspan="1" rowspan="1">0.98&#8211;1.43</td><td char="." align="char" colspan="1" rowspan="1">0.082</td></tr><tr><td align="left" colspan="1" rowspan="1">V2-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.03</td><td align="left" colspan="1" rowspan="1">0.72&#8211;1.49</td><td char="." align="char" colspan="1" rowspan="1">0.855</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.43</td><td align="left" colspan="1" rowspan="1">1.15&#8211;1.78</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.89</td><td align="left" colspan="1" rowspan="1">1.62&#8211;2.20</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol-lowering drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.85</td><td align="left" colspan="1" rowspan="1">0.68&#8211;1.07</td><td char="." align="char" colspan="1" rowspan="1">0.166</td></tr><tr><td align="left" colspan="1" rowspan="1">Eicosapentaenoic acid</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.15</td><td align="left" colspan="1" rowspan="1">0.92&#8211;1.42</td><td char="." align="char" colspan="1" rowspan="1">0.216</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">0.59&#8211;0.95</td><td char="." align="char" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9is</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.75&#8211;1.03</td><td char="." align="char" colspan="1" rowspan="1">0.117</td></tr></tbody></table><table-wrap-foot><p>The data shows the results of the multivariate analysis. GLP-1 receptor agonist. Imeglimin, and PCSK9is were excluded from the univariate analysis. </p><p><italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">HbA1c</italic> hemoglobin A1c, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate, <italic toggle="yes">HDL-C</italic> high-density lipoprotein cholesterol, <italic toggle="yes">LDL-C</italic> low-density lipoprotein cholesterol, <italic toggle="yes">TG</italic> triglycerides, <italic toggle="yes">CKD</italic> chronic kidney disease, <italic toggle="yes">DPP-4is</italic> dipeptidyl peptidase-4 inhibitors, <italic toggle="yes">GLP-1</italic> receptor agonists, glucagon-like peptide-1, <italic toggle="yes">SGLT2is</italic> sodium-glucose cotransporter 2 inhibitors, <italic toggle="yes">&#945;-GI</italic> alpha-glucosidase inhibitor, <italic toggle="yes">PDEis</italic> phosphodiesterase inhibitors, <italic toggle="yes">ACEis</italic> angiotensin-converting enzyme inhibitors, <italic toggle="yes">ARBs</italic> angiotensin II receptor blockers, <italic toggle="yes">ARNI</italic> angiotensin receptor-neprilysin inhibitor, <italic toggle="yes">V2-Receptor blockers</italic> vasopressin V2 receptor blockers.</p></table-wrap-foot></table-wrap>
</p><p id="Par10">Next, the OR for severe LEAD was calculated exclusively for patients with T2D diagnosed with LEAD (Tables&#160;<xref rid="Tab3" ref-type="table">3</xref>, <xref rid="Tab4" ref-type="table">4</xref>). The patient background exhibited trends similar to those of patients with T2D without a diagnosis of LEAD. The OR for severe LEAD showed a similar trend, with SGLT2is and fibrates showing lower ORs. Additionally, the GLP-1 receptor agonists and ezetimibe exhibited significantly lower ORs. Finally, Supplementary Table S3 presents a detailed analysis of the SGLT2is and fibrates. Among the SGLT2is, all components showed low ORs, with dapagliflozin, empagliflozin, and ipragliflozin demonstrating statistically significant values. Among the fibrates, pemafibrate exhibited the lowest value.</p><p id="Par11">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Baseline characteristics of patients with type 2 diabetes with lower extremity artery disease classified by the presence or absence of revascularization.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Characteristics</th><th align="left" colspan="1" rowspan="1">Overall (<italic toggle="yes">n</italic>&#8201;=&#8201;27,258)</th><th align="left" colspan="1" rowspan="1">Revasc (&#8722;) groups (<italic toggle="yes">n</italic>&#8201;=&#8201;26,368)</th><th align="left" colspan="1" rowspan="1">Revasc (+) groups (<italic toggle="yes">n</italic>&#8201;=&#8201;890)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex, n (%)</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">15,909 (58.4)</td><td align="left" colspan="1" rowspan="1">15,171 (57.5)</td><td align="left" colspan="1" rowspan="1">738 (82.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">11,349 (41.6)</td><td align="left" colspan="1" rowspan="1">11,197 (42.5)</td><td align="left" colspan="1" rowspan="1">152 (17.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1">Mean (years)</td><td align="left" colspan="1" rowspan="1">62.5&#8201;&#177;&#8201;7.6</td><td align="left" colspan="1" rowspan="1">62.4&#8201;&#177;&#8201;7.6</td><td align="left" colspan="1" rowspan="1">64.3&#8201;&#177;&#8201;0.5</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI</td><td align="left" colspan="1" rowspan="1">Mean (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">25.1&#8201;&#177;&#8201;4.2</td><td align="left" colspan="1" rowspan="1">25.1&#8201;&#177;&#8201;4.2</td><td align="left" colspan="1" rowspan="1">24.3&#8201;&#177;&#8201;3.7</td><td char="." align="char" colspan="1" rowspan="1">0.028</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">26,355 (96.7)</td><td align="left" colspan="1" rowspan="1">25,500 (96.7)</td><td align="left" colspan="1" rowspan="1">855 (96.1)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">903 (3.3)</td><td align="left" colspan="1" rowspan="1">868 (3.3)</td><td align="left" colspan="1" rowspan="1">35 (3.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">HbA1c</td><td align="left" colspan="1" rowspan="1">Mean (%)</td><td align="left" colspan="1" rowspan="1">6.8&#8201;&#177;&#8201;1.6</td><td align="left" colspan="1" rowspan="1">6.8&#8201;&#177;&#8201;1.6</td><td align="left" colspan="1" rowspan="1">7.0&#8201;&#177;&#8201;1.6</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">9585 (35.2)</td><td align="left" colspan="1" rowspan="1">9221 (35.0)</td><td align="left" colspan="1" rowspan="1">364 (40.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">17,673 (64.8)</td><td align="left" colspan="1" rowspan="1">17,147 (65.0)</td><td align="left" colspan="1" rowspan="1">526 (59.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR</td><td align="left" colspan="1" rowspan="1">Mean (mL/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">72.6&#8201;&#177;&#8201;19.7</td><td align="left" colspan="1" rowspan="1">72.9&#8201;&#177;&#8201;19.4</td><td align="left" colspan="1" rowspan="1">63.9&#8201;&#177;&#8201;23.6</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">21,509 (78.9)</td><td align="left" colspan="1" rowspan="1">20,954 (79.5)</td><td align="left" colspan="1" rowspan="1">555 (62.4)</td><td char="." align="char" rowspan="3" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30 -&lt;60</td><td align="left" colspan="1" rowspan="1">5216 (19.1)</td><td align="left" colspan="1" rowspan="1">4956 (18.8)</td><td align="left" colspan="1" rowspan="1">260 (29.2)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">533 (2.0)</td><td align="left" colspan="1" rowspan="1">458 (1.7)</td><td align="left" colspan="1" rowspan="1">75 (8.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure</td><td align="left" colspan="1" rowspan="1">Mean (mmHg)</td><td align="left" colspan="1" rowspan="1">81.6&#8201;&#177;&#8201;12.6</td><td align="left" colspan="1" rowspan="1">81.6&#8201;&#177;&#8201;12.6</td><td align="left" colspan="1" rowspan="1">81.0&#8201;&#177;&#8201;12.4</td><td char="." align="char" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;80</td><td align="left" colspan="1" rowspan="1">15,731 (57.7)</td><td align="left" colspan="1" rowspan="1">15,256 (57.9)</td><td align="left" colspan="1" rowspan="1">475 (53.4)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;80</td><td align="left" colspan="1" rowspan="1">11,527 (42.3)</td><td align="left" colspan="1" rowspan="1">11,112 (42.1)</td><td align="left" colspan="1" rowspan="1">415 (46.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure</td><td align="left" colspan="1" rowspan="1">Mean (mmHg)</td><td align="left" colspan="1" rowspan="1">139.9&#8201;&#177;&#8201;18.4</td><td align="left" colspan="1" rowspan="1">139.7&#8201;&#177;&#8201;18.3</td><td align="left" colspan="1" rowspan="1">145.8&#8201;&#177;&#8201;20.3</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;130</td><td align="left" colspan="1" rowspan="1">19,826 (72.7)</td><td align="left" colspan="1" rowspan="1">19,123 (72.5)</td><td align="left" colspan="1" rowspan="1">703 (79.0)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;130</td><td align="left" colspan="1" rowspan="1">7432 (27.3)</td><td align="left" colspan="1" rowspan="1">7245 (27.5)</td><td align="left" colspan="1" rowspan="1">187 (21.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL-C</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">64.3&#8201;&#177;&#8201;18.8</td><td align="left" colspan="1" rowspan="1">64.5&#8201;&#177;&#8201;18.9</td><td align="left" colspan="1" rowspan="1">59.4&#8201;&#177;&#8201;17.2</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;40</td><td align="left" colspan="1" rowspan="1">1585 (5.8)</td><td align="left" colspan="1" rowspan="1">1494 (5.7)</td><td align="left" colspan="1" rowspan="1">91 (10.2)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;40</td><td align="left" colspan="1" rowspan="1">25,673 (94.2)</td><td align="left" colspan="1" rowspan="1">24,874 (94.3)</td><td align="left" colspan="1" rowspan="1">799 (89.8)</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">128.7&#8201;&#177;&#8201;35.8</td><td align="left" colspan="1" rowspan="1">129.0&#8201;&#177;&#8201;35.7</td><td align="left" colspan="1" rowspan="1">122.3&#8201;&#177;&#8201;38.8</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;120</td><td align="left" colspan="1" rowspan="1">15,902 (58.3)</td><td align="left" colspan="1" rowspan="1">15,449 (58.6)</td><td align="left" colspan="1" rowspan="1">453 (50.9)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;120</td><td align="left" colspan="1" rowspan="1">11,356 (41.7)</td><td align="left" colspan="1" rowspan="1">10,919 (41.4)</td><td align="left" colspan="1" rowspan="1">437 (49.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">TG</td><td align="left" colspan="1" rowspan="1">Mean (mg/dL)</td><td align="left" colspan="1" rowspan="1">178.7&#8201;&#177;&#8201;147.2</td><td align="left" colspan="1" rowspan="1">178.0&#8201;&#177;&#8201;146.3</td><td align="left" colspan="1" rowspan="1">200.6&#8201;&#177;&#8201;171.2</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;150</td><td align="left" colspan="1" rowspan="1">12,896 (47.3)</td><td align="left" colspan="1" rowspan="1">12,422 (47.1)</td><td align="left" colspan="1" rowspan="1">474 (53.3)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;150</td><td align="left" colspan="1" rowspan="1">14,362 (52.7)</td><td align="left" colspan="1" rowspan="1">13,946 (52.9)</td><td align="left" colspan="1" rowspan="1">416 (46.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking history</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">23,579 (86.5)</td><td align="left" colspan="1" rowspan="1">22,942 (87.0)</td><td align="left" colspan="1" rowspan="1">637 (71.6)</td><td char="." align="char" rowspan="2" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">3679 (13.5)</td><td align="left" colspan="1" rowspan="1">3426 (13.0)</td><td align="left" colspan="1" rowspan="1">253 (28.4)</td></tr><tr><td align="left" colspan="1" rowspan="1">Drinking history</td><td align="left" colspan="1" rowspan="1">Every day</td><td align="left" colspan="1" rowspan="1">4714 (17.3)</td><td align="left" colspan="1" rowspan="1">4490 (17.0)</td><td align="left" colspan="1" rowspan="1">224 (25.1)</td><td char="." align="char" rowspan="4" colspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sometimes</td><td align="left" colspan="1" rowspan="1">4927 (18.1)</td><td align="left" colspan="1" rowspan="1">4755 (18.0)</td><td align="left" colspan="1" rowspan="1">172 (19.3)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Rarely</td><td align="left" colspan="1" rowspan="1">16,350 (60.0)</td><td align="left" colspan="1" rowspan="1">15,909 (60.3)</td><td align="left" colspan="1" rowspan="1">441 (49.6)</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">1267 (4.6)</td><td align="left" colspan="1" rowspan="1">1214 (4.7)</td><td align="left" colspan="1" rowspan="1">53 (6.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">Complication</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Angina</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9654 (35.4)</td><td align="left" colspan="1" rowspan="1">9169 (34.8)</td><td align="left" colspan="1" rowspan="1">485 (54.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Arrhythmia</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6919 (25.4)</td><td align="left" colspan="1" rowspan="1">6597 (25.0)</td><td align="left" colspan="1" rowspan="1">322 (36.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cerebral infraction</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">8822 (32.4)</td><td align="left" colspan="1" rowspan="1">8168 (31.0)</td><td align="left" colspan="1" rowspan="1">654 (73.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">CKD</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2924 (10.7)</td><td align="left" colspan="1" rowspan="1">2707 (10.3)</td><td align="left" colspan="1" rowspan="1">217 (24.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Heart failure</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9815 (36.0)</td><td align="left" colspan="1" rowspan="1">9275 (35.2)</td><td align="left" colspan="1" rowspan="1">540 (60.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hyperlipidemia</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">14,693 (53.9)</td><td align="left" colspan="1" rowspan="1">14,061 (53.3)</td><td align="left" colspan="1" rowspan="1">632 (71.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Hypertension</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">21,199 (77.8)</td><td align="left" colspan="1" rowspan="1">20,361 (77.2)</td><td align="left" colspan="1" rowspan="1">838 (94.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Myocardial infraction</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2402 (8.8)</td><td align="left" colspan="1" rowspan="1">2198 (8.3)</td><td align="left" colspan="1" rowspan="1">204 (22.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Neuropathy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13,758 (50.5)</td><td align="left" colspan="1" rowspan="1">13,293 (50.4)</td><td align="left" colspan="1" rowspan="1">465 (52.2)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Retinopathy</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9758 (35.8)</td><td align="left" colspan="1" rowspan="1">9394 (35.6)</td><td align="left" colspan="1" rowspan="1">364 (40.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-diabetic agent use</td><td align="left" colspan="1" rowspan="1">Distribution, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DPP-4is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">12,352 (45.3)</td><td align="left" colspan="1" rowspan="1">11,902 (45.1)</td><td align="left" colspan="1" rowspan="1">450 (50.6)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Glinides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2349 (8.6)</td><td align="left" colspan="1" rowspan="1">2270 (8.6)</td><td align="left" colspan="1" rowspan="1">79 (8.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 receptor agonists</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2160 (7.9)</td><td align="left" colspan="1" rowspan="1">2112 (8.0)</td><td align="left" colspan="1" rowspan="1">48 (5.4)</td><td char="." align="char" colspan="1" rowspan="1">0.241</td></tr><tr><td align="left" colspan="1" rowspan="1">Imeglimin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">237 (0.9)</td><td align="left" colspan="1" rowspan="1">234 (0.9)</td><td align="left" colspan="1" rowspan="1">3 (0.3)</td><td char="." align="char" colspan="1" rowspan="1">0.212</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6356 (23.3)</td><td align="left" colspan="1" rowspan="1">6049 (22.9)</td><td align="left" colspan="1" rowspan="1">307 (34.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">9682 (35.5)</td><td align="left" colspan="1" rowspan="1">9408 (35.7)</td><td align="left" colspan="1" rowspan="1">274 (30.8)</td><td char="." align="char" colspan="1" rowspan="1">0.981</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7624 (28.0)</td><td align="left" colspan="1" rowspan="1">7435 (28.2)</td><td align="left" colspan="1" rowspan="1">189 (21.2)</td><td char="." align="char" colspan="1" rowspan="1">0.068</td></tr><tr><td align="left" colspan="1" rowspan="1">Sulfonylureas</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4027 (14.8)</td><td align="left" colspan="1" rowspan="1">3852 (14.6)</td><td align="left" colspan="1" rowspan="1">175 (19.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazolidinediones</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2248 (8.2)</td><td align="left" colspan="1" rowspan="1">2174 (8.2)</td><td align="left" colspan="1" rowspan="1">74 (8.3)</td><td char="." align="char" colspan="1" rowspan="1">0.073</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-GIs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3791 (13.9)</td><td align="left" colspan="1" rowspan="1">3646 (13.8)</td><td align="left" colspan="1" rowspan="1">145 (16.3)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiplatelet drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">6176 (22.7)</td><td align="left" colspan="1" rowspan="1">5727 (21.7)</td><td align="left" colspan="1" rowspan="1">449 (50.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">P2Y12is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4434 (16.3)</td><td align="left" colspan="1" rowspan="1">4042 (15.3)</td><td align="left" colspan="1" rowspan="1">392 (44.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PDEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1674 (6.1)</td><td align="left" colspan="1" rowspan="1">1409 (5.3)</td><td align="left" colspan="1" rowspan="1">265 (29.8)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antihypertensive drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ACEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2011 (7.4)</td><td align="left" colspan="1" rowspan="1">1904 (7.2)</td><td align="left" colspan="1" rowspan="1">107 (12.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Aldosterone receptor blocker</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2238 (8.2)</td><td align="left" colspan="1" rowspan="1">2098 (8.0)</td><td align="left" colspan="1" rowspan="1">140 (15.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARBs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">13,838 (50.8)</td><td align="left" colspan="1" rowspan="1">13,192 (50.0)</td><td align="left" colspan="1" rowspan="1">646 (72.6)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARNI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">581 (2.1)</td><td align="left" colspan="1" rowspan="1">536 (2.0)</td><td align="left" colspan="1" rowspan="1">45 (5.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium channel blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15,440 (56.6)</td><td align="left" colspan="1" rowspan="1">14,704 (55.8)</td><td align="left" colspan="1" rowspan="1">736 (82.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Loop diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">3667 (13.5)</td><td align="left" colspan="1" rowspan="1">3423 (13.0)</td><td align="left" colspan="1" rowspan="1">244 (27.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazide diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2545 (9.3)</td><td align="left" colspan="1" rowspan="1">2390 (9.1)</td><td align="left" colspan="1" rowspan="1">155 (17.4)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">V2-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">474 (1.7)</td><td align="left" colspan="1" rowspan="1">432 (1.6)</td><td align="left" colspan="1" rowspan="1">42 (4.7)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1245 (4.6)</td><td align="left" colspan="1" rowspan="1">1128 (4.3)</td><td align="left" colspan="1" rowspan="1">117 (13.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7709 (28.3)</td><td align="left" colspan="1" rowspan="1">7251 (27.5)</td><td align="left" colspan="1" rowspan="1">458 (51.5)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol-lowering drug use</td><td align="left" colspan="1" rowspan="1">Distribution,&#160;n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2961 (10.9)</td><td align="left" colspan="1" rowspan="1">2863 (10.9)</td><td align="left" colspan="1" rowspan="1">98 (11.0)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Eicosapentaenoic acid</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2741 (10.1)</td><td align="left" colspan="1" rowspan="1">2635 (10.0)</td><td align="left" colspan="1" rowspan="1">106 (11.9)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2825 (10.4)</td><td align="left" colspan="1" rowspan="1">2745 (10.4)</td><td align="left" colspan="1" rowspan="1">80 (9.0)</td><td char="." align="char" colspan="1" rowspan="1">0.560</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">51 (0.2)</td><td align="left" colspan="1" rowspan="1">50 (0.2)</td><td align="left" colspan="1" rowspan="1">1 (0.1)</td><td char="." align="char" colspan="1" rowspan="1">0.676</td></tr><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15,899 (58.3)</td><td align="left" colspan="1" rowspan="1">15,337 (58.2)</td><td align="left" colspan="1" rowspan="1">562 (63.1)</td><td char="." align="char" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr></tbody></table><table-wrap-foot><p>Data are presented as numbers (%) or means (standard deviations). The <italic toggle="yes">P</italic> values were calculated for the differences between patients with Revasc or without Revasc. </p><p>
<italic toggle="yes"> Revasc</italic> revascularization, <italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">HbA1c</italic> hemoglobin A1c, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate, <italic toggle="yes">HDL-C</italic> high-density lipoprotein cholesterol, <italic toggle="yes">LDL-C</italic> low-density lipoprotein cholesterol, <italic toggle="yes">TG</italic> triglycerides, <italic toggle="yes">CKD</italic> chronic kidney disease, <italic toggle="yes">DPP-4is</italic> dipeptidyl peptidase-4 inhibitors, <italic toggle="yes">GLP-1</italic> receptor agonists, glucagon-like peptide-1, <italic toggle="yes">SGLT2is</italic> sodium-glucose cotransporter 2 inhibitors, <italic toggle="yes">&#945;-GI</italic> alpha-glucosidase inhibitor, <italic toggle="yes">PDEis</italic> phosphodiesterase inhibitors, <italic toggle="yes">ACEis</italic> angiotensin-converting enzyme inhibitors, <italic toggle="yes">ARBs</italic> angiotensin II receptor blockers, <italic toggle="yes">ARNI</italic> angiotensin receptor-neprilysin inhibitor, <italic toggle="yes">V2-Receptor blockers</italic> vasopressin V2 receptor blockers.</p></table-wrap-foot></table-wrap>
</p><p id="Par12">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Logistic regression analysis of factors associated with the implementation of revascularization in patients with type 2 diabetes and lower extremity artery disease.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1"/><th align="left" colspan="1" rowspan="1">Odds ratio</th><th align="left" colspan="1" rowspan="1">95% CI</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1">Male</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Female</td><td align="left" colspan="1" rowspan="1">0.46</td><td align="left" colspan="1" rowspan="1">0.36&#8211;0.60</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Age/10years</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.25</td><td align="left" colspan="1" rowspan="1">1.08&#8211;1.45</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;18.5</td><td align="left" colspan="1" rowspan="1">2.00</td><td align="left" colspan="1" rowspan="1">1.25&#8211;3.18</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">HbA1c (%)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;7.0</td><td align="left" colspan="1" rowspan="1">0.66</td><td align="left" colspan="1" rowspan="1">0.52&#8211;0.82</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">eGFR (mL/min/1.73m<sup>2</sup>)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;60</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">30 to &lt;60</td><td align="left" colspan="1" rowspan="1">1.26</td><td align="left" colspan="1" rowspan="1">1.04&#8211;1.54</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;30</td><td align="left" colspan="1" rowspan="1">2.21</td><td align="left" colspan="1" rowspan="1">1.48&#8211;3.29</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Diastolic blood pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;80</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;80</td><td align="left" colspan="1" rowspan="1">1.48</td><td align="left" colspan="1" rowspan="1">1.22&#8211;1.79</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Systolic blood pressure (mmHg)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;130</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;130</td><td align="left" colspan="1" rowspan="1">0.91</td><td align="left" colspan="1" rowspan="1">0.73&#8211;1.15</td><td align="left" colspan="1" rowspan="1">0.426</td></tr><tr><td align="left" colspan="1" rowspan="1">HDL-C (mg/dL)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;40</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8805;&#8201;40</td><td align="left" colspan="1" rowspan="1">0.96</td><td align="left" colspan="1" rowspan="1">0.71&#8211;1.31</td><td align="left" colspan="1" rowspan="1">0.81</td></tr><tr><td align="left" colspan="1" rowspan="1">LDL-C (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;120</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;120</td><td align="left" colspan="1" rowspan="1">0.90</td><td align="left" colspan="1" rowspan="1">0.75&#8211;1.07</td><td align="left" colspan="1" rowspan="1">0.23</td></tr><tr><td align="left" colspan="1" rowspan="1">TG (mg/dL)</td><td align="left" colspan="1" rowspan="1">&#8805;&#8201;150</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&lt;&#8201;150</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">0.65&#8211;0.92</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking history</td><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Yes</td><td align="left" colspan="1" rowspan="1">1.98</td><td align="left" colspan="1" rowspan="1">1.63&#8211;2.40</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Drinking history</td><td align="left" colspan="1" rowspan="1">Every day</td><td align="left" colspan="1" rowspan="1">Reference</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Sometimes</td><td align="left" colspan="1" rowspan="1">1.20</td><td align="left" colspan="1" rowspan="1">0.98&#8211;1.47</td><td align="left" colspan="1" rowspan="1">0.081</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">Rarely</td><td align="left" colspan="1" rowspan="1">1.35</td><td align="left" colspan="1" rowspan="1">1.06&#8211;1.73</td><td align="left" colspan="1" rowspan="1">0.015</td></tr><tr><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">No</td><td align="left" colspan="1" rowspan="1">1.26</td><td align="left" colspan="1" rowspan="1">0.87&#8211;1.81</td><td align="left" colspan="1" rowspan="1">0.224</td></tr><tr><td align="left" colspan="1" rowspan="1">Anti-diabetic agent use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DPP-4is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.98</td><td align="left" colspan="1" rowspan="1">0.79&#8211;1.21</td><td align="left" colspan="1" rowspan="1">0.839</td></tr><tr><td align="left" colspan="1" rowspan="1">Glinides</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">GLP-1 receptor agonists</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.56</td><td align="left" colspan="1" rowspan="1">0.37&#8211;0.85</td><td align="left" colspan="1" rowspan="1">0.006</td></tr><tr><td align="left" colspan="1" rowspan="1">Imeglimin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.07</td><td align="left" colspan="1" rowspan="1">0.33&#8211;3.49</td><td align="left" colspan="1" rowspan="1">0.915</td></tr><tr><td align="left" colspan="1" rowspan="1">Insulin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">0.82&#8211;1.25</td><td align="left" colspan="1" rowspan="1">0.909</td></tr><tr><td align="left" colspan="1" rowspan="1">Metformin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.72</td><td align="left" colspan="1" rowspan="1">0.58&#8211;0.90</td><td align="left" colspan="1" rowspan="1">0.004</td></tr><tr><td align="left" colspan="1" rowspan="1">SGLT2is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.52</td><td align="left" colspan="1" rowspan="1">0.42&#8211;0.66</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Sulfonylureas</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.21</td><td align="left" colspan="1" rowspan="1">0.95&#8211;1.55</td><td align="left" colspan="1" rowspan="1">0.122</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazolidinediones</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-GIs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.03</td><td align="left" colspan="1" rowspan="1">0.80&#8211;1.32</td><td align="left" colspan="1" rowspan="1">0.828</td></tr><tr><td align="left" colspan="1" rowspan="1">Antiplatelet drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Aspirin</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.40</td><td align="left" colspan="1" rowspan="1">1.14&#8211;1.72</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">P2Y12is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">2.25</td><td align="left" colspan="1" rowspan="1">1.83&#8211;2.76</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">PDEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">4.34</td><td align="left" colspan="1" rowspan="1">3.56&#8211;5.28</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Antihypertensive drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">ACEis</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.67&#8211;1.16</td><td align="left" colspan="1" rowspan="1">0.368</td></tr><tr><td align="left" colspan="1" rowspan="1">Aldosterone receptor blocker</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.21</td><td align="left" colspan="1" rowspan="1">0.92&#8211;1.60</td><td align="left" colspan="1" rowspan="1">0.166</td></tr><tr><td align="left" colspan="1" rowspan="1">ARBs</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.39</td><td align="left" colspan="1" rowspan="1">1.14&#8211;1.71</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">ARNI</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.25</td><td align="left" colspan="1" rowspan="1">0.82&#8211;1.92</td><td align="left" colspan="1" rowspan="1">0.292</td></tr><tr><td align="left" colspan="1" rowspan="1">Calcium channel blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.97</td><td align="left" colspan="1" rowspan="1">1.55&#8211;2.49</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Loop diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.09</td><td align="left" colspan="1" rowspan="1">0.86&#8211;1.39</td><td align="left" colspan="1" rowspan="1">0.466</td></tr><tr><td align="left" colspan="1" rowspan="1">Thiazide diuretics</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.06</td><td align="left" colspan="1" rowspan="1">0.83&#8211;1.35</td><td align="left" colspan="1" rowspan="1">0.641</td></tr><tr><td align="left" colspan="1" rowspan="1">V2-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.11</td><td align="left" colspan="1" rowspan="1">0.70&#8211;1.75</td><td align="left" colspan="1" rowspan="1">0.667</td></tr><tr><td align="left" colspan="1" rowspan="1">&#945;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.53</td><td align="left" colspan="1" rowspan="1">1.17&#8211;2.00</td><td align="left" colspan="1" rowspan="1">0.002</td></tr><tr><td align="left" colspan="1" rowspan="1">&#946;-Receptor blockers</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.54</td><td align="left" colspan="1" rowspan="1">1.28&#8211;1.86</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Cholesterol-lowering drug use</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ezetimibe</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.72</td><td align="left" colspan="1" rowspan="1">0.54&#8211;0.95</td><td align="left" colspan="1" rowspan="1">0.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Eicosapentaenoic acid</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.88</td><td align="left" colspan="1" rowspan="1">0.67&#8211;1.15</td><td align="left" colspan="1" rowspan="1">0.354</td></tr><tr><td align="left" colspan="1" rowspan="1">Fibrates</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">0.51&#8211;0.92</td><td align="left" colspan="1" rowspan="1">0.012</td></tr><tr><td align="left" colspan="1" rowspan="1">PCSK9is</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">&#8211;</td></tr><tr><td align="left" colspan="1" rowspan="1">Statins</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.89</td><td align="left" colspan="1" rowspan="1">0.73&#8211;1.07</td><td align="left" colspan="1" rowspan="1">0.217</td></tr></tbody></table><table-wrap-foot><p>The data shows the results of the multivariate analysis. Glinides, thiazolidinediones, and PCSK9is were excluded from the univariate analysis.</p><p><italic toggle="yes">BMI</italic> body mass index, <italic toggle="yes">CI</italic> confidence interval, <italic toggle="yes">HbA1c</italic> hemoglobin A1c, <italic toggle="yes">eGFR</italic> estimated glomerular filtration rate, <italic toggle="yes">HDL-C</italic> high-density lipoprotein cholesterol, <italic toggle="yes">LDL-C</italic> low-density lipoprotein cholesterol, <italic toggle="yes">TG</italic> triglycerides, <italic toggle="yes">CKD</italic> chronic kidney disease, <italic toggle="yes">DPP-4is</italic> dipeptidyl peptidase-4 inhibitors, <italic toggle="yes">GLP-1</italic> receptor agonists, glucagon-like peptide-1, <italic toggle="yes">SGLT2is</italic> sodium-glucose cotransporter 2 inhibitors, <italic toggle="yes">&#945;-GI</italic> alpha-glucosidase inhibitor, <italic toggle="yes">PDEis</italic> phosphodiesterase inhibitors, <italic toggle="yes">ACEis</italic> angiotensin-converting enzyme inhibitors, <italic toggle="yes">ARBs</italic> angiotensin II receptor blockers, <italic toggle="yes">ARNI</italic> angiotensin receptor-neprilysin inhibitor, <italic toggle="yes">V2-Receptor blockers</italic> vasopressin V2 receptor blockers.</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec3"><title>Discussion</title><p id="Par13">Our study indicates that SGLT2is, metformin, and fibrates may contribute to the attenuation of LEAD severity in individuals with T2D. This trend was consistently observed even when the analysis was confined to patients with T2D who had been diagnosed with LEAD. Both SGLT2is and metformin, which are foundational therapies for T2D, exhibit distinct, yet complementary mechanisms for mitigating atherosclerosis risk. SGLT2is primarily lower plasma glucose levels by promoting urinary glucose excretion and confer additional cardiovascular benefits, including weight reduction, blood pressure lowering, improved lipid profiles, and anti-inflammatory effects<sup><xref ref-type="bibr" rid="CR28">28</xref>&#8211;<xref ref-type="bibr" rid="CR30">30</xref></sup>. These multifaceted actions are pivotal for the prevention of atherosclerosis, particularly in patients with concurrent obesity or hypertension. Conversely, metformin reduces glucose levels by inhibiting hepatic gluconeogenesis and enhancing insulin sensitivity<sup><xref ref-type="bibr" rid="CR31">31</xref>,<xref ref-type="bibr" rid="CR32">32</xref></sup>. Through its activation of adenosine monophosphate-activated protein kinase (AMPK), metformin exerts anti-inflammatory and endothelial-protective effects<sup><xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref></sup> while also improving lipid metabolism and diminishing thrombogenic potential. Unlike SGLT2is, metformin does not directly influence body weight or blood pressure but delivers substantial metabolic and vascular benefits<sup><xref ref-type="bibr" rid="CR36">36</xref>&#8211;<xref ref-type="bibr" rid="CR38">38</xref></sup>. In this study, insulin use was significantly associated with a higher OR for severe LEAD. This finding may be attributed to insulin being typically prescribed to patients with a longer duration of T2D. Longer diabetes duration is often associated with more advanced atherosclerosis and increased vascular complications, including LEAD. Furthermore, insulin-treated patients often have a history of poor glycemic control, which may contribute to progressive vascular damage. Although the observed association is statistically significant, the underlying mechanisms require further investigation to clarify the relationship between insulin use and LEAD progression. Numerous studies have highlighted the pleiotropic effects of fibrates, including the stabilization of atheromatous plaques, anti-inflammatory properties, and lipid-lowering effects<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR40">40</xref></sup>. These multifaceted actions may play a significant role in mitigating the progression of LEAD. In the present study, the use of pemafibrate was associated with a reduced OR for Revasc in patients with LEAD. Pemafibrate is a tissue-specific PPAR&#945; agonist, classified as a selective PPAR modulator alpha (SPPARM&#945;), that significantly lowers the risk of severe LEAD. This effect is attributed to two key factors: SPPARM&#945; is more effective than conventional fibrates in improving TG, HDL-C, non-HDL-C, and very low-density lipoprotein levels<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>; and pemafibrate has been shown to induce favorable modifications in the size and composition of atherogenic lipoproteins<sup><xref ref-type="bibr" rid="CR42">42</xref></sup>. This makes pemafibrate a promising therapeutic option for lipid management in the prevention of LEAD progression in patients with T2D. Additionally, ezetimibe significantly reduced the OR for Revasc in patients with T2D and LEAD. Notably, 93.9% of patients who received ezetimibe had a history of previous statin therapy, suggesting that the observed anti-atherosclerotic effect may result from a synergistic interaction between ezetimibe and statins. This combination may enhance the efficacy of cholesterol control, especially in patients at high cardiovascular risk. In contrast, other medications, such as certain antihypertensive or antiplatelet agents, do not offer comparable vascular protection or glycemic control, which may limit their effectiveness in preventing LEAD progression.</p><p id="Par14">Meta-analyses of previous studies have reported that a 1% increase in HbA1c levels is associated with a 15% increase in the incidence of macrovascular complications in patients with type 1 diabetes and an 18% increase in those with T2D<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Intensified blood glucose control therapy has been shown to reduce the risk of myocardial infarction and lower-limb amputations<sup><xref ref-type="bibr" rid="CR44">44</xref>,<xref ref-type="bibr" rid="CR45">45</xref></sup>. However, the Japanese LEAD guidelines note that there is insufficient evidence to suggest that blood glucose control provides preventive benefits. This study provides new insights into this regard.</p><p id="Par15">In previous studies, risk factors for CLTI have been assessed, with factors such as advanced age, renal dysfunction, smoking, and low BMI commonly reported as significant risk factors<sup><xref ref-type="bibr" rid="CR46">46</xref>&#8211;<xref ref-type="bibr" rid="CR56">56</xref></sup>. Recent research has also identified frailty and maintenance dialysis<sup><xref ref-type="bibr" rid="CR57">57</xref>,<xref ref-type="bibr" rid="CR58">58</xref></sup> as important risk factors for CLTI, which aligns with the findings of the present study. The Appropriate Blood Pressure Control in Diabetes study (ABCD study)<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>, which included 950 patients with diabetes, demonstrated that aggressive blood pressure control significantly reduced the incidence of cardiovascular events compared with placebo without exacerbating lower limb symptoms. Conversely, the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT)<sup><xref ref-type="bibr" rid="CR60">60</xref></sup> showed a U-shaped correlation between sBp and outcomes, with optimal levels between 120 and 129 mmHg. In the current study, among 67,693 patients with T2D whose sBP was less than 130 mmHg, 37.6% had an sBP of less than 120 mmHg, which may explain the lack of significant findings in the OR. In contrast, a dBP of less than 60 mmHg was observed in 4.0% of the 98,062 patients, which yielded a significantly higher OR, suggesting that maintaining a higher dBP may be beneficial for preserving blood flow to the lower limbs. It is speculated that the high OR of antihypertensive and antiplatelet drugs in this study was due to their administration in high-risk patients, leading to a possible reversal of causality. The lack of significance observed for statins may be attributed to the fact that a substantial percentage of patients with LEAD in this study were already receiving statin therapy, which is typically prescribed more actively to patients with atherosclerosis. Finally, the relationship between lipid-related parameters-namely, LDL-C, HDL-C, and TG levels, and severe LEAD was examined. High LDL-C, high TG, and low HDL-C levels have been identified as risk factors for the worsening of LEAD<sup><xref ref-type="bibr" rid="CR5">5</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>. Previous studies conducted in Japan have also shown a close association between these lipid abnormalities and the concomitant occurrence of LEAD<sup><xref ref-type="bibr" rid="CR62">62</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. However, in the current study, LDL-C and HDL levels, the cutoff values of which were set based on current guidelines, did not show significance, whereas TG levels of less than 150&#160;mg/dL were associated with a decreased OR. Patients with high LDL-C and low HDL-C levels require more aggressive statin or fibrate treatment. Moreover, LDL-C and HDL-C levels were lower in patients with significantly impaired renal function, suggesting a potential influence of various patient characteristics. Nevertheless, further investigation is warranted because the reasons for this could not be clearly elucidated. In contrast, when TG levels were within the cutoff value, the OR of severe LEAD was significantly reduced in patients with LEAD. Oh et al.<sup><xref ref-type="bibr" rid="CR64">64</xref></sup> also reported that Intima-Media Thickness was significantly decreased with a TG level of less than 150&#160;mg/dL. We speculate that achieving the cutoff value for TGs in this study may have suppressed atherosclerosis and reduced the risk of severe LEAD. The clinical implications of these findings emphasize the importance of comprehensive management strategies for LEAD, incorporating pharmacological therapies alongside lifestyle modifications, including exercise and smoking cessation. Clinicians should consider the individual characteristics of patients, including age, kidney function, and comorbidities, when selecting medications to manage LEAD and prevent its progression.</p><p id="Par16">This study has a few limitations that must be considered when interpreting the findings. First, the DeSC database mainly covers employment and self-employed insurance, and since the insurance system in Japan changes from 75 years of age and above, much of the data for this age group are missing. Second, the severity of LEAD was assessed by performing Revasc; however, the ABI could not be investigated. Therefore, the exact severity of LEAD could not be determined. This may be subjective to evaluators. Therefore, a prospective study is required to validate our results. Third, severe LEAD was investigated as an outcome in this study. Generally, advanced LEAD is diagnosed as CLTI using the WIfI classification. However, since the claims database does not provide information necessary for the WIfI classification, such as subjective symptoms, it was not possible to define CLTI. Consequently, it was necessary to define the outcome as severe LEAD. Fourth, only 30% of the patients had available laboratory data. As these patients may have unknown factors that were not included in the analysis, their impact on the results cannot be ruled out. Fifth, in individuals near the upper age limit of the database (75 years), the observation period may be relatively short, affecting the assessment of LEAD progression over time. This limitation should be considered when interpreting findings for older patients. Finally, the high ORs observed for antihypertensive and antiplatelet drugs may result from their use in high-risk patients, suggesting a potential reversal of causality. However, it remains unclear whether patients&#8217; condition severity was fully adjusted for in the analysis. Future studies incorporating more comprehensive analyses of patient severity, medication dosage and duration may be required to validate these findings. Previous studies have shown that overlapping risk factors can increase the risk of LEAD onset by 1.5 to 10 times<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. LEAD is also frequently associated with other atherosclerotic diseases, such as CVD, and is associated with a 1.5- to 2-fold higher risk of cardiovascular events even after adjustment for age<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. Therefore, comprehensive management of risk factors is essential not only to prevent the development and progression of LEAD, but also to improve overall prognosis. However, LEAD is often underrecognized in clinical practice, and even when diagnosed, its management tends to be inadequate<sup><xref ref-type="bibr" rid="CR67">67</xref>&#8211;<xref ref-type="bibr" rid="CR70">70</xref></sup>. Beyond pharmacological treatment, a comprehensive risk management approach&#8212;including lifestyle interventions such as exercise and smoking cessation&#8212;should be regarded as a fundamental aspect of LEAD care. These findings support the necessity of individualized patient management in the clinical setting.</p><p id="Par17">In conclusion, the active use of SGLT2is, metformin, and fibrates may be beneficial in preventing LEAD progression. However, these medications are associated with a higher incidence of adverse events, particularly among elderly patients or those with impaired kidney function. Careful individualized patient management is essential to maximize the benefits of these treatments. Future studies further evaluating the factors associated with LEAD may be required to validate these findings and inform guidelines for LEAD prevention and management. Additionally, to establish accurate causal relationships, randomized controlled trials are necessary.</p></sec><sec id="Sec4"><title>Materials and methods</title><sec id="Sec5"><title>Study design</title><p id="Par18">This retrospective cross-sectional study utilized data from the DeSC database (DeSC Healthcare, Inc., Tokyo, Japan), which includes anonymized health insurance claims collected via a web-based platform (kencom) operated by DeSC Healthcare Inc. The database integrates information from two categories of insurers: corporate health insurance associations covering employees of large Japanese companies and their dependents (&lt;&#8201;75 years old), and national health insurance providers for self-employed individuals and others not covered by other insurance (&lt;&#8201;75 years old). Health insurance claims data included: patient demographics; diagnoses coded according to the International Classification of Diseases, 10th Revision (ICD-10); medical procedures; and monthly prescription details. The health checkup data encompassed results from annual physical examinations, biomarker assessments, imaging studies (e.g., chest X-rays), and questionnaire responses addressing medical history, comorbidities, medication usage, and lifestyle factors such as smoking. Additional self-reported data, including responses to the Work Productivity and Activity Impairment Questionnaire, were gathered via a web-based system. Data were anonymized through an &#8220;opt-out agreement&#8221; with users, who were informed of the potential utilization of their data and their right to request deletion. DeSC encrypts all patient data to ensure anonymity for database users. This study analyzed the data collected between April 1, 2014 and October 30, 2023. Prescription records and information on targeted medications were reviewed for the period spanning the diagnosis of LEAD and the subsequent endovascular treatment.</p></sec><sec id="Sec6"><title>Ethical considerations</title><p id="Par19">This study was conducted in accordance with the Declaration of Helsinki and the Ethical Guidelines for Medical and Health Research Involving Human Subjects. This study was approved by the Ethical Committee of Musashino University (No. R6-7). Since unlinked, anonymized data were used, the ethics committee confirmed that this study was not subject to compliance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects, Due to the retrospective nature of the study, the Ethical Committee of Musashino University waived the need of obtaining informed consent.</p></sec><sec id="Sec7"><title>Study population</title><p id="Par20">First, the data of 1,463,445 patients with diabetes mellitus (ICD-10 codes: E11&#8211;E14) registered between April 1, 2014 and October 30, 2023, in the DeSC claim database were extracted (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>). Next, patients with T2D were selected based on their most recent diabetes-related ICD-10 code. The following patients were excluded: patients diagnosed with type 1 diabetes (<italic toggle="yes">n</italic>&#8201;=&#8201;53,768), patients diagnosed with any other diabetes mellitus (<italic toggle="yes">n</italic>&#8201;=&#8201;666,127), and patients with missing basic baseline information (<italic toggle="yes">n</italic>&#8201;=&#8201;499,944). Finally, 243,606 patients with T2D were included and subsequently divided into two groups: patients with T2D diagnosed with LEAD undergoing Revasc (<italic toggle="yes">n</italic>&#8201;=&#8201;890) and patients with T2D not undergoing Revasc (<italic toggle="yes">n</italic>&#8201;=&#8201;242,716). In the subgroup analysis, we focused exclusively on patients with T2D who were diagnosed with LEAD. Hence, patients with T2D who did not have a diagnosis of LEAD (<italic toggle="yes">n</italic>&#8201;=&#8201;216,348) were excluded. Finally, 27,258 patients with T2D who were diagnosed with LEAD were included and subsequently divided into two groups: patients with T2D diagnosed with LEAD and undergoing Revasc (<italic toggle="yes">n</italic>=]890) and patients with T2D diagnosed with LEAD and not undergoing Revasc (<italic toggle="yes">n</italic>&#8201;=&#8201;26,368).</p><p id="Par21">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Patient disposition. <italic toggle="yes">LEAD</italic> lower extremity artery disease, <italic toggle="yes">T1D</italic> type 1 diabetes, <italic toggle="yes">T2D</italic> type 2 diabetes, <italic toggle="yes">Revasc</italic> revasculation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e4004" position="float" orientation="portrait" xlink:href="41598_2025_3797_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec8"><title>Identification of complications, use of concomitant drugs, and revasc events</title><p id="Par22">Complications were identified based on ICD-10 codes, assigned up to the time of Revasc implementation for patients who underwent Revasc, and throughout the observation period for those who did not. Concomitant medications were investigated using the same approach. Revasc events were defined as medical procedures classified as Revasc that were performed after the assignment of the ICD-10 code for LEAD. Revasc encompassed medical procedures such as bypass surgery and EVT. The severity of LEAD and its complications were assessed following the criteria established in a prior study by Felix et al.<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>, which defined the severity of diabetic complications. To ensure the accuracy of database coding for complications and procedures, we relied on the adapted Diabetes Complications Severity Index (DCSI), which uses ICD-10 codes to identify and classify diabetes-related complications. This method has been validated in previous studies<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>, which demonstrated the reliability of the DCSI in assessing complications in patients with diabetes. The DeSC database also undergoes regular audits and validation checks to verify the accuracy of clinical event codes, further ensuring the reliability of the data used in this study. Using these validated tools and processes supports the credibility of these findings and minimizes potential coding errors. The Revasc procedures examined in this study are detailed in Supplementary Table <xref rid="MOESM1" ref-type="media">S1</xref>.</p></sec><sec id="Sec9"><title>Outcomes</title><p id="Par23">Revasc is recommended as a treatment option in patients with T2D and LEAD who present with ischemic rest pain or exercise-induced claudication if symptoms are inadequately managed by pharmacotherapy or exercise therapy<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. In the present study, severe LEAD was defined as a diagnosis of LEAD for which Revasc was performed.</p></sec><sec id="Sec10"><title>Patient characteristics</title><p id="Par24">Age, sex, body mass index (BMI), and laboratory data were identified using data recorded in the claim records closest to the start of the observation period. Being underweight was defined by a BMI of less than 18.5&#160;kg/m<sup>2</sup>. Laboratory data were collected to determine the estimated glomerular filtration rate (eGFR), hemoglobin A1c (HbA1c), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglyceride (TG), diastolic blood pressure (dBp), and systolic blood pressure (sBp).</p></sec><sec id="Sec11"><title>Statistical analysis</title><p id="Par25">Normally distributed data (age, BMI, eGFR, HbA1c, HDL-C, LDL-C, TG, dBP, and sBp) are expressed as means&#8201;&#177;&#8201;standard deviations and were analyzed using an unpaired <italic toggle="yes">t</italic>-test. Categorical variables are expressed as absolute numbers or percentages and analyzed using the &#967;<sup>2</sup> or Fisher&#8217;s exact test. The cutoffs were set at less than 7.0% for HbA1c; 40&#160;mg/dL or more for HDL; less than 120&#160;mg/dL for LDL; less than 150&#160;mg/dL for TGs; less than 30 mL/min/1.73 m<sup>2</sup>, and between 30 and 60 mL/min/1.73 m<sup>2</sup> for eGFR; less than 80 mmHg for dBP; and less than 130 mmHG for sBp, according to the guidelines<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Variables significantly associated with severe LEAD were identified using univariate logistic regression. Those with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.2 were included in the multivariate model. To reduce potential multicollinearity, although formal diagnostics (e.g., variance inflation factors) were not performed, variable selection was guided by both statistical significance and clinical relevance.&#12288;Risks are expressed as odds ratios (ORs) with their corresponding 95% confidence intervals (CIs). This study excluded patients with missing baseline data from the analysis. As a result, there was no need to handle missing data within the analysis population. We used forced entry methods to include clinically relevant variables, such as patient background and known risk factors for LEAD progression. Forced entry ensures that all key factors are included, regardless of statistical significance. Regarding multicollinearity, clinically important factors were prioritized, and comorbidities were excluded due to suspected high collinearity with concomitant medications. Regarding the criteria for exclusion of variables, particularly comorbidities, we considered the potential for multicollinearity between diagnosis codes and concomitant medications. In our dataset, it was difficult to distinguish between individuals who were diagnosed but not treated (e.g., due to mild or subclinical disease), and those who received a diagnosis for administrative or screening purposes without clinical confirmation. Since pharmacological treatment often follows clinical diagnosis, we assumed that medication use could serve as a more reliable proxy for clinically significant disease than diagnosis codes alone. Including both medication and diagnosis variables in the same model could lead to multicollinearity and obscure true associations. Therefore, we prioritized the inclusion of medication variables to minimize potential misclassification and enhance the robustness of the model.&#12288;All statistical analyses were performed using IBM SPSS Statistics for Windows version 23.0 (IBM Corp., Armonk, NY, USA). Statistical significance was set at a <italic toggle="yes">P</italic>-value of less than 0.05.</p></sec></sec><sec id="Sec12" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="41598_2025_3797_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by Grants for DAIGAKUTOKUBETSU&#12288;KENKYUHI&#12288;Grant from the Musashino University (O6-172).</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>T.H. and conceptualized the study; T.H. and Y.I. performed literature search; T.H. analysed the data and statistical analysis; T.H, M.K, Y.I, Y.O, A.S and K.M. analyzed the results; T.H. wrote the manuscript.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>The data that support the findings of this study are available from DeSC database but restrictions apply to the availability of these data, which were used under licence for the current study, and so are not publicly available. Data are, however, available from the corresponding author, Takeshi Horii (t-horii@musashino-u.ac.jp), upon reasonable request and with permission from DeSC Healthcare, Inc.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par26">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stolar</surname><given-names>M</given-names></name></person-group><article-title>Glycemic control and complications in type 2 diabetes mellitus</article-title><source>Am. J. Med.</source><year>2010</year><volume>123</volume><fpage>S3</fpage><lpage>S11</lpage><pub-id pub-id-type="doi">10.1016/j.amjmed.2009.12.004</pub-id><pub-id pub-id-type="pmid">20206730</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Stolar, M. Glycemic control and complications in type 2 diabetes mellitus. <italic toggle="yes">Am. J. Med.</italic><bold>123</bold>, S3&#8211;S11. 10.1016/j.amjmed.2009.12.004 (2010).<pub-id pub-id-type="pmid">20206730</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2009.12.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>LeRoith</surname><given-names>D</given-names></name><name name-style="western"><surname>Rayfield</surname><given-names>EJ</given-names></name></person-group><article-title>The benefits of tight glycemic control in type 2 diabetes mellitus</article-title><source>Clin. Cornerstone</source><year>2007</year><volume>8</volume><fpage>S19</fpage><lpage>S29</lpage><pub-id pub-id-type="doi">10.1016/s1098-3597(07)80018-4</pub-id><pub-id pub-id-type="pmid">18159646</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">LeRoith, D. &amp; Rayfield, E. J. The benefits of tight glycemic control in type 2 diabetes mellitus. <italic toggle="yes">Clin. Cornerstone</italic>. <bold>8</bold>, S19&#8211;S29. 10.1016/s1098-3597(07)80018-4 (2007).<pub-id pub-id-type="pmid">18159646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1098-3597(07)80018-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meeuwisse-Pasterkamp</surname><given-names>SH</given-names></name><name name-style="western"><surname>van der Klauw</surname><given-names>MM</given-names></name><name name-style="western"><surname>Wolffenbuttel</surname><given-names>BHR</given-names></name></person-group><article-title>Type 2 diabetes mellitus: prevention of macrovascular complications</article-title><source>Expert Rev. Cardiovasc. Ther.</source><year>2008</year><volume>6</volume><fpage>323</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1586/14779072.6.3.323</pub-id><pub-id pub-id-type="pmid">18327994</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Meeuwisse-Pasterkamp, S. H., van der Klauw, M. M. &amp; Wolffenbuttel, B. H. R. Type 2 diabetes mellitus: prevention of macrovascular complications. <italic toggle="yes">Expert Rev. Cardiovasc. Ther.</italic><bold>6</bold>, 323&#8211;341. 10.1586/14779072.6.3.323 (2008).<pub-id pub-id-type="pmid">18327994</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14779072.6.3.323</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prompers</surname><given-names>L</given-names></name><etal/></person-group><article-title>High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe: baseline results from the Eurodiale study</article-title><source>Diabetologia</source><year>2007</year><volume>50</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1007/s00125-006-0491-1</pub-id><pub-id pub-id-type="pmid">17093942</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Prompers, L. et al. High prevalence of ischaemia, infection and serious comorbidity in patients with diabetic foot disease in Europe: baseline results from the Eurodiale study. <italic toggle="yes">Diabetologia</italic><bold>50</bold>, 18&#8211;25. 10.1007/s00125-006-0491-1 (2007).<pub-id pub-id-type="pmid">17093942</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00125-006-0491-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>P</given-names></name><etal/></person-group><article-title>Global, regional, and National prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis</article-title><source>Lancet Glob. Health</source><year>2019</year><volume>7</volume><fpage>e1020</fpage><lpage>e1030</lpage><pub-id pub-id-type="doi">10.1016/S2214-109X(19)30255-4</pub-id><pub-id pub-id-type="pmid">31303293</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Song, P. et al. Global, regional, and National prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. <italic toggle="yes">Lancet Glob. Health</italic>. <bold>7</bold>, e1020&#8211;e1030. 10.1016/S2214-109X(19)30255-4 (2019).<pub-id pub-id-type="pmid">31303293</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2214-109X(19)30255-4</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Japan&#8217;s Ministry of Health, Labour and Welfare. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka.pdf">https://www.mhlw.go.jp/bunya/kenkou/eiyou09/dl/01-kekka.pdf</ext-link></mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsey</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Incidence, outcomes, and cost of foot ulcers in patients with diabetes</article-title><source>Diabetes Care</source><year>1999</year><volume>22</volume><fpage>382</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.2337/diacare.22.3.382</pub-id><pub-id pub-id-type="pmid">10097914</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Ramsey, S. D. et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. <italic toggle="yes">Diabetes Care</italic>. <bold>22</bold>, 382&#8211;387. 10.2337/diacare.22.3.382 (1999).<pub-id pub-id-type="pmid">10097914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.22.3.382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>CA</given-names></name><name name-style="western"><surname>Vileikyte</surname><given-names>L</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>S</given-names></name><name name-style="western"><surname>Carrington</surname><given-names>AL</given-names></name><name name-style="western"><surname>Boulton</surname><given-names>AJ</given-names></name></person-group><article-title>Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration</article-title><source>Diabetes Care</source><year>1998</year><volume>21</volume><fpage>1071</fpage><lpage>1075</lpage><pub-id pub-id-type="doi">10.2337/diacare.21.7.1071</pub-id><pub-id pub-id-type="pmid">9653597</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Abbott, C. A., Vileikyte, L., Williamson, S., Carrington, A. L. &amp; Boulton, A. J. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. <italic toggle="yes">Diabetes Care</italic>. <bold>21</bold>, 1071&#8211;1075. 10.2337/diacare.21.7.1071 (1998).<pub-id pub-id-type="pmid">9653597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/diacare.21.7.1071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abbott</surname><given-names>CA</given-names></name><etal/></person-group><article-title>The North-West diabetes foot care study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort</article-title><source>Diabet. Med.</source><year>2002</year><volume>19</volume><fpage>377</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1046/j.1464-5491.2002.00698.x</pub-id><pub-id pub-id-type="pmid">12027925</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Abbott, C. A. et al. The North-West diabetes foot care study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. <italic toggle="yes">Diabet. Med.</italic><bold>19</bold>, 377&#8211;384. 10.1046/j.1464-5491.2002.00698.x (2002).<pub-id pub-id-type="pmid">12027925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1464-5491.2002.00698.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takahara</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases</article-title><source>Cardiovasc. Diabetol.</source><year>2019</year><volume>18</volume><fpage>155</fpage><pub-id pub-id-type="doi">10.1186/s12933-019-0955-5</pub-id><pub-id pub-id-type="pmid">31730004</pub-id><pub-id pub-id-type="pmcid">PMC6857236</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Takahara, M. et al. Diabetes mellitus and other cardiovascular risk factors in lower-extremity peripheral artery disease versus coronary artery disease: an analysis of 1,121,359 cases from the nationwide databases. <italic toggle="yes">Cardiovasc. Diabetol.</italic><bold>18</bold>, 155. 10.1186/s12933-019-0955-5 (2019).<pub-id pub-id-type="pmid">31730004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12933-019-0955-5</pub-id><pub-id pub-id-type="pmcid">PMC6857236</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maeda</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes: the Kyushu prevention study for atherosclerosis</article-title><source>Diabetes Res. Clin. Pract.</source><year>2008</year><volume>82</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.diabres.2008.09.008</pub-id><pub-id pub-id-type="pmid">18930561</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Maeda, Y. et al. High prevalence of peripheral arterial disease diagnosed by low ankle-brachial index in Japanese patients with diabetes: the Kyushu prevention study for atherosclerosis. <italic toggle="yes">Diabetes Res. Clin. Pract.</italic><bold>82</bold>, 378&#8211;382. 10.1016/j.diabres.2008.09.008 (2008).<pub-id pub-id-type="pmid">18930561</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.diabres.2008.09.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Natsuaki</surname><given-names>C</given-names></name><etal/></person-group><article-title>Association of borderline ankle-brachial index with mortality and the incidence of peripheral artery disease in diabetic patients</article-title><source>Atherosclerosis</source><year>2014</year><volume>234</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2014.03.018</pub-id><pub-id pub-id-type="pmid">24732575</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Natsuaki, C. et al. Association of borderline ankle-brachial index with mortality and the incidence of peripheral artery disease in diabetic patients. <italic toggle="yes">Atherosclerosis</italic><bold>234</bold>, 360&#8211;365. 10.1016/j.atherosclerosis.2014.03.018 (2014).<pub-id pub-id-type="pmid">24732575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2014.03.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eraso</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Peripheral arterial disease, prevalence and cumulative risk factor profile analysis</article-title><source>Eur. J. Prev. Cardiol.</source><year>2014</year><volume>21</volume><fpage>704</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1177/2047487312452968</pub-id><pub-id pub-id-type="pmid">22739687</pub-id><pub-id pub-id-type="pmcid">PMC4436703</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Eraso, L. H. et al. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. <italic toggle="yes">Eur. J. Prev. Cardiol.</italic><bold>21</bold>, 704&#8211;711. 10.1177/2047487312452968 (2014).<pub-id pub-id-type="pmid">22739687</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487312452968</pub-id><pub-id pub-id-type="pmcid">PMC4436703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigvant</surname><given-names>B</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>F</given-names></name><name name-style="western"><surname>Wahlberg</surname><given-names>E</given-names></name></person-group><article-title>The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral arterial disease</article-title><source>Eur. J. Vasc Endovasc. Surg.</source><year>2016</year><volume>51</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2015.10.022</pub-id><pub-id pub-id-type="pmid">26777541</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Sigvant, B., Lundin, F. &amp; Wahlberg, E. The risk of disease progression in peripheral arterial disease is higher than expected: A meta-analysis of mortality and disease progression in peripheral arterial disease. <italic toggle="yes">Eur. J. Vasc Endovasc. Surg.</italic><bold>51</bold>, 395&#8211;403. 10.1016/j.ejvs.2015.10.022 (2016).<pub-id pub-id-type="pmid">26777541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2015.10.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siracuse</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease</article-title><source>J. Vasc Surg.</source><year>2012</year><volume>55</volume><fpage>1001</fpage><lpage>1007</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2011.10.128</pub-id><pub-id pub-id-type="pmid">22301210</pub-id><pub-id pub-id-type="pmcid">PMC3319263</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Siracuse, J. J. et al. Results for primary bypass versus primary angioplasty/stent for intermittent claudication due to superficial femoral artery occlusive disease. <italic toggle="yes">J. Vasc Surg.</italic><bold>55</bold>, 1001&#8211;1007. 10.1016/j.jvs.2011.10.128 (2012).<pub-id pub-id-type="pmid">22301210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2011.10.128</pub-id><pub-id pub-id-type="pmcid">PMC3319263</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giannopoulos</surname><given-names>S</given-names></name><etal/></person-group><article-title>Three-year outcomes from the LIBERTY 360 study of endovascular interventions for peripheral artery disease stratified by Rutherford category</article-title><source>J. Endovasc. Ther.</source><year>2021</year><volume>28</volume><fpage>262</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1177/1526602820962972</pub-id><pub-id pub-id-type="pmid">33016805</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Giannopoulos, S. et al. Three-year outcomes from the LIBERTY 360 study of endovascular interventions for peripheral artery disease stratified by Rutherford category. <italic toggle="yes">J. Endovasc. Ther.</italic><bold>28</bold>, 262&#8211;274. 10.1177/1526602820962972 (2021).<pub-id pub-id-type="pmid">33016805</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1526602820962972</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baubeta Fridh</surname><given-names>E</given-names></name><etal/></person-group><article-title>Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population-based study</article-title><source>Eur. J. Vasc Endovasc. Surg.</source><year>2017</year><volume>54</volume><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2017.07.005</pub-id><pub-id pub-id-type="pmid">28797662</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Baubeta Fridh, E. et al. Amputation rates, mortality, and pre-operative comorbidities in patients revascularised for intermittent claudication or critical limb ischaemia: a population-based study. <italic toggle="yes">Eur. J. Vasc Endovasc. Surg.</italic><bold>54</bold>, 480&#8211;486. 10.1016/j.ejvs.2017.07.005 (2017).<pub-id pub-id-type="pmid">28797662</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2017.07.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soga</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease</article-title><source>Circ. J.</source><year>2010</year><volume>74</volume><fpage>1689</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.1253/circj.cj-10-0077</pub-id><pub-id pub-id-type="pmid">20574137</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Soga, Y. et al. Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease. <italic toggle="yes">Circ. J.</italic><bold>74</bold>, 1689&#8211;1695. 10.1253/circj.cj-10-0077 (2010).<pub-id pub-id-type="pmid">20574137</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1253/circj.cj-10-0077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saraidaridis</surname><given-names>JT</given-names></name><etal/></person-group><article-title>The natural history and outcomes of endovascular therapy for claudication</article-title><source>Ann. Vasc. Surg.</source><year>2017</year><volume>44</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2017.04.021</pub-id><pub-id pub-id-type="pmid">28479467</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Saraidaridis, J. T. et al. The natural history and outcomes of endovascular therapy for claudication. <italic toggle="yes">Ann. Vasc. Surg.</italic><bold>44</bold>, 34&#8211;40. 10.1016/j.avsg.2017.04.021 (2017).<pub-id pub-id-type="pmid">28479467</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.avsg.2017.04.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dillingham</surname><given-names>TR</given-names></name><name name-style="western"><surname>Pezzin</surname><given-names>LE</given-names></name><name name-style="western"><surname>Shore</surname><given-names>AD</given-names></name></person-group><article-title>Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations</article-title><source>Arch. Phys. Med. Rehabil.</source><year>2005</year><volume>86</volume><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1016/j.apmr.2004.06.072</pub-id><pub-id pub-id-type="pmid">15759232</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dillingham, T. R., Pezzin, L. E. &amp; Shore, A. D. Reamputation, mortality, and health care costs among persons with dysvascular lower-limb amputations. <italic toggle="yes">Arch. Phys. Med. Rehabil</italic>. <bold>86</bold>, 480&#8211;486. 10.1016/j.apmr.2004.06.072 (2005).<pub-id pub-id-type="pmid">15759232</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.apmr.2004.06.072</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kono</surname><given-names>Y</given-names></name><name name-style="western"><surname>Muder</surname><given-names>RR</given-names></name></person-group><article-title>Identifying the incidence of and risk factors for reamputation among patients who underwent foot amputation</article-title><source>Ann. Vasc. Surg.</source><year>2012</year><volume>26</volume><fpage>1120</fpage><lpage>1126</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2012.02.011</pub-id><pub-id pub-id-type="pmid">22840342</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kono, Y. &amp; Muder, R. R. Identifying the incidence of and risk factors for reamputation among patients who underwent foot amputation. <italic toggle="yes">Ann. Vasc. Surg.</italic><bold>26</bold>, 1120&#8211;1126. 10.1016/j.avsg.2012.02.011 (2012).<pub-id pub-id-type="pmid">22840342</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.avsg.2012.02.011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beaulieu</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Rates and predictors of readmission after minor lower extremity amputations</article-title><source>J. Vasc. Surg.</source><year>2015</year><volume>62</volume><fpage>101</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2015.02.021</pub-id><pub-id pub-id-type="pmid">25827965</pub-id><pub-id pub-id-type="pmcid">PMC4801218</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Beaulieu, R. J. et al. Rates and predictors of readmission after minor lower extremity amputations. <italic toggle="yes">J. Vasc. Surg.</italic><bold>62</bold>, 101&#8211;105. 10.1016/j.jvs.2015.02.021 (2015).<pub-id pub-id-type="pmid">25827965</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2015.02.021</pub-id><pub-id pub-id-type="pmcid">PMC4801218</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoffmann</surname><given-names>M</given-names></name><etal/></person-group><article-title>Survival of diabetes patients with major amputation is comparable to malignant disease</article-title><source>Diabetes Vasc. Dis. Res.</source><year>2015</year><volume>12</volume><fpage>265</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1177/1479164115579005</pub-id><pub-id pub-id-type="pmid">25920914</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hoffmann, M. et al. Survival of diabetes patients with major amputation is comparable to malignant disease. <italic toggle="yes">Diabetes Vasc. Dis. Res.</italic><bold>12</bold>, 265&#8211;271. 10.1177/1479164115579005 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/1479164115579005</pub-id><pub-id pub-id-type="pmid">25920914</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><etal/></person-group><article-title>International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1001/jama.295.2.180</pub-id><pub-id pub-id-type="pmid">16403930</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Bhatt, D. L. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. <italic toggle="yes">JAMA</italic><bold>295</bold>, 180&#8211;189. 10.1001/jama.295.2.180 (2006).<pub-id pub-id-type="pmid">16403930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.2.180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pande</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Secondary prevention and mortality in peripheral artery disease: National health and nutrition examination study, 1999 to 2004</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.003954</pub-id><pub-id pub-id-type="pmid">21690489</pub-id><pub-id pub-id-type="pmcid">PMC3139992</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Pande, R. L. et al. Secondary prevention and mortality in peripheral artery disease: National health and nutrition examination study, 1999 to 2004. <italic toggle="yes">Circulation</italic><bold>124</bold>, 17&#8211;23. 10.1161/CIRCULATIONAHA.110.003954 (2011).<pub-id pub-id-type="pmid">21690489</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.110.003954</pub-id><pub-id pub-id-type="pmcid">PMC3139992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welten</surname><given-names>GMJM</given-names></name><etal/></person-group><article-title>Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease</article-title><source>J. Am. Coll. Cardiol.</source><year>2008</year><volume>51</volume><fpage>1588</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.11.077</pub-id><pub-id pub-id-type="pmid">18420103</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Welten, G. M. J. M. et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. <italic toggle="yes">J. Am. Coll. Cardiol.</italic><bold>51</bold>, 1588&#8211;1596. 10.1016/j.jacc.2007.11.077 (2008).<pub-id pub-id-type="pmid">18420103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2007.11.077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Non-coronary atherosclerosis</article-title><source>Eur. Heart J.</source><year>2014</year><volume>35</volume><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu071</pub-id><pub-id pub-id-type="pmid">24595865</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Gallino, A. et al. Non-coronary atherosclerosis. <italic toggle="yes">Eur. Heart J.</italic><bold>35</bold>, 1112&#8211;1119. 10.1093/eurheartj/ehu071 (2014).<pub-id pub-id-type="pmid">24595865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehu071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>PC</given-names></name><name name-style="western"><surname>Ganguly</surname><given-names>S</given-names></name><name name-style="western"><surname>Goh</surname><given-names>SY</given-names></name></person-group><article-title>Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms</article-title><source>Obes. Rev.</source><year>2018</year><volume>19</volume><fpage>1630</fpage><lpage>1641</lpage><pub-id pub-id-type="doi">10.1111/obr.12755</pub-id><pub-id pub-id-type="pmid">30253050</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Lee, P. C., Ganguly, S. &amp; Goh, S. Y. Weight loss associated with sodium-glucose cotransporter-2 inhibition: a review of evidence and underlying mechanisms. <italic toggle="yes">Obes. Rev.</italic><bold>19</bold>, 1630&#8211;1641. 10.1111/obr.12755 (2018).<pub-id pub-id-type="pmid">30253050</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/obr.12755</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chiriac&#242;</surname><given-names>M</given-names></name><name name-style="western"><surname>Tric&#242;</surname><given-names>D</given-names></name><name name-style="western"><surname>Solini</surname><given-names>A</given-names></name></person-group><article-title>Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors</article-title><source>Curr. Opin. Pharmacol.</source><year>2022</year><volume>66</volume><fpage>102272</fpage><pub-id pub-id-type="doi">10.1016/j.coph.2022.102272</pub-id><pub-id pub-id-type="pmid">35964531</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Chiriac&#242;, M., Tric&#242;, D. &amp; Solini, A. Mechanisms of cardio-renal protection of sodium-glucose cotransporter-2 inhibitors. <italic toggle="yes">Curr. Opin. Pharmacol.</italic><bold>66</bold>, 102272. 10.1016/j.coph.2022.102272 (2022).<pub-id pub-id-type="pmid">35964531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.coph.2022.102272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lazarte</surname><given-names>J</given-names></name><name name-style="western"><surname>Kanagalingam</surname><given-names>T</given-names></name><name name-style="western"><surname>Hegele</surname><given-names>RA</given-names></name></person-group><article-title>Lipid effects of sodium-glucose cotransporter 2 inhibitors</article-title><source>Curr. Opin. Lipidol.</source><year>2021</year><volume>32</volume><fpage>183</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1097/MOL.0000000000000751</pub-id><pub-id pub-id-type="pmid">33870930</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Lazarte, J., Kanagalingam, T. &amp; Hegele, R. A. Lipid effects of sodium-glucose cotransporter 2 inhibitors. <italic toggle="yes">Curr. Opin. Lipidol.</italic><bold>32</bold>, 183&#8211;190. 10.1097/MOL.0000000000000751 (2021).<pub-id pub-id-type="pmid">33870930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOL.0000000000000751</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bahne</surname><given-names>E</given-names></name><etal/></person-group><article-title>Involvement of glucagon-like peptide-1 in the glucose-lowering effect of Metformin</article-title><source>Diabetes Obes. Metab.</source><year>2016</year><volume>18</volume><fpage>955</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1111/dom.12697</pub-id><pub-id pub-id-type="pmid">27265206</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Bahne, E. et al. Involvement of glucagon-like peptide-1 in the glucose-lowering effect of Metformin. <italic toggle="yes">Diabetes Obes. Metab.</italic><bold>18</bold>, 955&#8211;961. 10.1111/dom.12697 (2016).<pub-id pub-id-type="pmid">27265206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/dom.12697</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avijit</surname><given-names>M</given-names></name><name name-style="western"><surname>Ashini</surname><given-names>S</given-names></name></person-group><article-title>A review on metformin: clinical significance and side effects</article-title><source>Res. J. Pharm. Technol.</source><year>2021</year><volume>14</volume><fpage>6179</fpage><lpage>6186</lpage><pub-id pub-id-type="doi">10.52711/0974-360X.2021.01070</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Avijit, M. &amp; Ashini, S. A review on metformin: clinical significance and side effects. <italic toggle="yes">Res. J. Pharm. Technol.</italic><bold>14</bold>, 6179&#8211;6186. 10.52711/0974-360X.2021.01070 (2021).</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Salt</surname><given-names>IP</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>TM</given-names></name></person-group><article-title>Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation</article-title><source>Expert Opin. Investig. Drugs</source><year>2012</year><volume>21</volume><fpage>1155</fpage><lpage>1167</lpage><pub-id pub-id-type="doi">10.1517/13543784.2012.696609</pub-id><pub-id pub-id-type="pmid">22694351</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Salt, I. P. &amp; Palmer, T. M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. <italic toggle="yes">Expert Opin. Investig. Drugs</italic>. <bold>21</bold>, 1155&#8211;1167. 10.1517/13543784.2012.696609 (2012).<pub-id pub-id-type="pmid">22694351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/13543784.2012.696609</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>Z</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>R</given-names></name><name name-style="western"><surname>Neumann</surname><given-names>D</given-names></name><name name-style="western"><surname>Zou</surname><given-names>MH</given-names></name></person-group><article-title>Phosphorylation of LKB1 at Serine 428 by protein kinase C-&#950; is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells</article-title><source>Circulation</source><year>2011</year><volume>117</volume><fpage>952</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.107.744490</pub-id><pub-id pub-id-type="pmcid">PMC2862466</pub-id><pub-id pub-id-type="pmid">18250273</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Xie, Z., Dong, Y., Scholz, R., Neumann, D. &amp; Zou, M. H. Phosphorylation of LKB1 at Serine 428 by protein kinase C-&#950; is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. <italic toggle="yes">Circulation</italic><bold>117</bold>, 952&#8211;962. 10.1161/CIRCULATIONAHA.107.744490 (2011).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.107.744490</pub-id><pub-id pub-id-type="pmcid">PMC2862466</pub-id><pub-id pub-id-type="pmid">18250273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>R</given-names></name><name name-style="western"><surname>Wu</surname><given-names>W</given-names></name><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z</given-names></name></person-group><article-title>AMP-activated protein kinase: an attractive therapeutic target for ischemia-reperfusion injury</article-title><source>Eur. J. Pharmacol.</source><year>2020</year><volume>888</volume><fpage>173484</fpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173484</pub-id><pub-id pub-id-type="pmid">32798506</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Ding, R., Wu, W., Sun, Z. &amp; Li, Z. AMP-activated protein kinase: an attractive therapeutic target for ischemia-reperfusion injury. <italic toggle="yes">Eur. J. Pharmacol.</italic><bold>888</bold>, 173484. 10.1016/j.ejphar.2020.173484 (2020).<pub-id pub-id-type="pmid">32798506</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejphar.2020.173484</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Bakhshaei, S. et al. Impact of Metformin on hypertension: current knowledge. <italic toggle="yes">J. Ren. Endocrinol.</italic><bold>8</bold>10.34172/jre.2022.25067 (2022).</mixed-citation></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>H</given-names></name><etal/></person-group><article-title>Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial</article-title><source>J. Hypertens.</source><year>2012</year><volume>30</volume><fpage>1430</fpage><lpage>1439</lpage><pub-id pub-id-type="doi">10.1097/HJH.0b013e328353e249</pub-id><pub-id pub-id-type="pmid">22525206</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">He, H. et al. Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial. <italic toggle="yes">J. Hypertens.</italic><bold>30</bold>, 1430&#8211;1439. 10.1097/HJH.0b013e328353e249 (2012).<pub-id pub-id-type="pmid">22525206</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/HJH.0b013e328353e249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway</article-title><source>Hypertens. Res.</source><year>2019</year><volume>42</volume><fpage>960</fpage><lpage>969</lpage><pub-id pub-id-type="doi">10.1038/s41440-019-0212-z</pub-id><pub-id pub-id-type="pmid">30664704</pub-id><pub-id pub-id-type="pmcid">PMC6571038</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Chen, C. et al. Metformin prevents vascular damage in hypertension through the AMPK/ER stress pathway. <italic toggle="yes">Hypertens. Res.</italic><bold>42</bold>, 960&#8211;969. 10.1038/s41440-019-0212-z (2019).<pub-id pub-id-type="pmid">30664704</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41440-019-0212-z</pub-id><pub-id pub-id-type="pmcid">PMC6571038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Keech, A. et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. <italic toggle="yes">Lancet</italic> 366, 1849&#8211;1861. 10.1016/S0140-6736(05)67667-2 (2005). (<bold>Erratum in: Lancet 368, 1420 (2006). Doi: 10.1016/S0140-6736(06)69595-0</bold>)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(05)67667-2</pub-id><pub-id pub-id-type="pmid">16310551</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fruchart</surname><given-names>JC</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-alpha (PPAR&#945;): at the crossroads of obesity, diabetes and cardiovascular disease</article-title><source>Atherosclerosis</source><year>2009</year><volume>205</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.03.008</pub-id><pub-id pub-id-type="pmid">19386311</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Fruchart, J. C. Peroxisome proliferator-activated receptor-alpha (PPAR&#945;): at the crossroads of obesity, diabetes and cardiovascular disease. <italic toggle="yes">Atherosclerosis</italic><bold>205</bold>, 1&#8211;8. 10.1016/j.atherosclerosis.2009.03.008 (2009).<pub-id pub-id-type="pmid">19386311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2009.03.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araki</surname><given-names>E</given-names></name><etal/></person-group><article-title>Effects of pemafibrate, a novel selective PPAR&#945; modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><fpage>538</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.2337/dc17-1589</pub-id><pub-id pub-id-type="pmid">29298800</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Araki, E. et al. Effects of pemafibrate, a novel selective PPAR&#945; modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. <italic toggle="yes">Diabetes Care</italic>. <bold>41</bold>, 538&#8211;546. 10.2337/dc17-1589 (2018).<pub-id pub-id-type="pmid">29298800</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc17-1589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishibashi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effects of K-877, a novel selective PPAR&#945; modulator (SPPARM&#945;), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial</article-title><source>Atherosclerosis</source><year>2016</year><volume>249</volume><fpage>36</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2016.02.029</pub-id><pub-id pub-id-type="pmid">27062408</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Ishibashi, S. et al. Effects of K-877, a novel selective PPAR&#945; modulator (SPPARM&#945;), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. <italic toggle="yes">Atherosclerosis</italic><bold>249</bold>, 36&#8211;43. 10.1016/j.atherosclerosis.2016.02.029 (2016).<pub-id pub-id-type="pmid">27062408</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2016.02.029</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Selvin</surname><given-names>E</given-names></name><etal/></person-group><article-title>Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus</article-title><source>Ann. Intern. Med.</source><year>2004</year><volume>141</volume><fpage>421</fpage><lpage>431</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-141-6-200409210-00007</pub-id><pub-id pub-id-type="pmid">15381515</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Selvin, E. et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. <italic toggle="yes">Ann. Intern. Med.</italic><bold>141</bold>, 421&#8211;431. 10.7326/0003-4819-141-6-200409210-00007 (2004).<pub-id pub-id-type="pmid">15381515</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7326/0003-4819-141-6-200409210-00007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boussageon</surname><given-names>R</given-names></name><etal/></person-group><article-title>Effect of intensive glucose Lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials</article-title><source>BMJ</source><year>2011</year><volume>343</volume><fpage>d4169</fpage><pub-id pub-id-type="doi">10.1136/bmj.d4169</pub-id><pub-id pub-id-type="pmid">21791495</pub-id><pub-id pub-id-type="pmcid">PMC3144314</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Boussageon, R. et al. Effect of intensive glucose Lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. <italic toggle="yes">BMJ</italic><bold>343</bold>, d4169. 10.1136/bmj.d4169 (2011).<pub-id pub-id-type="pmid">21791495</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.d4169</pub-id><pub-id pub-id-type="pmcid">PMC3144314</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hasan</surname><given-names>R</given-names></name><etal/></person-group><article-title>A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome</article-title><source>J. Vasc. Surg.</source><year>2016</year><volume>63</volume><issue>Suppl</issue><fpage>22S</fpage><lpage>28Se1</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2015.10.005</pub-id><pub-id pub-id-type="pmid">26804364</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Hasan, R. et al. A systematic review and meta-analysis of glycemic control for the prevention of diabetic foot syndrome. <italic toggle="yes">J. Vasc. Surg.</italic><bold>63</bold> (Suppl), 22S&#8211;28Se1. 10.1016/j.jvs.2015.10.005 (2016).<pub-id pub-id-type="pmid">26804364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2015.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Senda</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predictive value of underweight status for patients with peripheral artery disease with claudication</article-title><source>Angiology</source><year>2018</year><volume>69</volume><fpage>513</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1177/0003319717736627</pub-id><pub-id pub-id-type="pmid">29088925</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Senda, K. et al. Predictive value of underweight status for patients with peripheral artery disease with claudication. <italic toggle="yes">Angiology</italic><bold>69</bold>, 513&#8211;522. 10.1177/0003319717736627 (2018).<pub-id pub-id-type="pmid">29088925</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/0003319717736627</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bradbury</surname><given-names>AW</given-names></name><etal/></person-group><article-title>Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making</article-title><source>J. Vasc. Surg.</source><year>2010</year><volume>51</volume><issue>Suppl</issue><fpage>52S</fpage><lpage>68S</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2010.01.077</pub-id><pub-id pub-id-type="pmid">20435262</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Bradbury, A. W. et al. Bypass versus angioplasty in severe ischaemia of the leg (BASIL) trial: a survival prediction model to facilitate clinical decision making. <italic toggle="yes">J. Vasc. Surg.</italic><bold>51</bold> (Suppl), 52S&#8211;68S. 10.1016/j.jvs.2010.01.077 (2010).<pub-id pub-id-type="pmid">20435262</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2010.01.077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiraki</surname><given-names>T</given-names></name><etal/></person-group><article-title>Predictive scoring model of mortality after surgical or endovascular revascularization in patients with critical limb ischemia</article-title><source>J. Vasc. Surg.</source><year>2014</year><volume>60</volume><fpage>383</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2014.02.059</pub-id><pub-id pub-id-type="pmid">24726827</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Shiraki, T. et al. Predictive scoring model of mortality after surgical or endovascular revascularization in patients with critical limb ischemia. <italic toggle="yes">J. Vasc. Surg.</italic><bold>60</bold>, 383&#8211;389. 10.1016/j.jvs.2014.02.059 (2014).<pub-id pub-id-type="pmid">24726827</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2014.02.059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soga</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Two-year life expectancy in patients with critical limb ischemia</article-title><source>JACC Cardiovasc. Interv.</source><year>2014</year><volume>7</volume><fpage>1444</fpage><lpage>1449</lpage><pub-id pub-id-type="doi">10.1016/j.jcin.2014.06.018</pub-id><pub-id pub-id-type="pmid">25523536</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Soga, Y. et al. Two-year life expectancy in patients with critical limb ischemia. <italic toggle="yes">JACC Cardiovasc. Interv</italic>. <bold>7</bold>, 1444&#8211;1449. 10.1016/j.jcin.2014.06.018 (2014).<pub-id pub-id-type="pmid">25523536</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcin.2014.06.018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azuma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Predictive model for mortality risk including the wound, ischemia, foot infection classification in patients undergoing revascularization for critical limb ischemia</article-title><source>Circ. Cardiovasc. Interv.</source><year>2019</year><volume>12</volume><fpage>e008015</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.119.008015</pub-id><pub-id pub-id-type="pmid">31771341</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Azuma, N. et al. Predictive model for mortality risk including the wound, ischemia, foot infection classification in patients undergoing revascularization for critical limb ischemia. <italic toggle="yes">Circ. Cardiovasc. Interv</italic>. <bold>12</bold>, e008015. 10.1161/CIRCINTERVENTIONS.119.008015 (2019).<pub-id pub-id-type="pmid">31771341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.119.008015</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiraki</surname><given-names>T</given-names></name><etal/></person-group><article-title>SPINACH study investigators. Baseline and updated information on nutritional status in patients with chronic limb-threatening ischaemia undergoing revascularisation</article-title><source>Eur. J. Vasc. Endovasc. Surg.</source><year>2021</year><volume>61</volume><fpage>467</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2020.11.036</pub-id><pub-id pub-id-type="pmid">33358104</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Shiraki, T. et al. SPINACH study investigators. Baseline and updated information on nutritional status in patients with chronic limb-threatening ischaemia undergoing revascularisation. <italic toggle="yes">Eur. J. Vasc. Endovasc. Surg.</italic><bold>61</bold>, 467&#8211;472 (2021).<pub-id pub-id-type="pmid">33358104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2020.11.036</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hata</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Risk stratification for 2-year mortality in patients with chronic limb-threatening ischemia undergoing endovascular therapy</article-title><source>J. Atheroscler. Thromb.</source><year>2021</year><volume>28</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.5551/jat.57711</pub-id><pub-id pub-id-type="pmid">32713933</pub-id><pub-id pub-id-type="pmcid">PMC8193785</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Hata, Y. et al. Risk stratification for 2-year mortality in patients with chronic limb-threatening ischemia undergoing endovascular therapy. <italic toggle="yes">J. Atheroscler. Thromb.</italic><bold>28</bold>, 477&#8211;482. 10.5551/jat.57711 (2021).<pub-id pub-id-type="pmid">32713933</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.57711</pub-id><pub-id pub-id-type="pmcid">PMC8193785</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Meltzer</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>The comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative risk assessment for patients with critical limb ischemia</article-title><source>J. Vasc. Surg.</source><year>2013</year><volume>57</volume><fpage>1186</fpage><lpage>1195</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2012.09.083</pub-id><pub-id pub-id-type="pmid">23375435</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Meltzer, A. J. et al. The comprehensive risk assessment for bypass (CRAB) facilitates efficient perioperative risk assessment for patients with critical limb ischemia. <italic toggle="yes">J. Vasc. Surg.</italic><bold>57</bold>, 1186&#8211;1195. 10.1016/j.jvs.2012.09.083 (2013).<pub-id pub-id-type="pmid">23375435</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2012.09.083</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Simons</surname><given-names>JP</given-names></name><etal/></person-group><article-title>A comparative evaluation of risk-adjustment models for benchmarking amputation-free survival after lower extremity bypass</article-title><source>J. Vasc. Surg.</source><year>2016</year><volume>63</volume><fpage>990</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2015.09.051</pub-id><pub-id pub-id-type="pmid">26603547</pub-id><pub-id pub-id-type="pmcid">PMC5315434</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Simons, J. P. et al. A comparative evaluation of risk-adjustment models for benchmarking amputation-free survival after lower extremity bypass. <italic toggle="yes">J. Vasc. Surg.</italic><bold>63</bold>, 990&#8211;997. 10.1016/j.jvs.2015.09.051 (2016).<pub-id pub-id-type="pmid">26603547</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2015.09.051</pub-id><pub-id pub-id-type="pmcid">PMC5315434</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moxey</surname><given-names>PW</given-names></name><etal/></person-group><article-title>The BASIL survival prediction model in patients with peripheral arterial disease undergoing revascularization in a university hospital setting and comparison with the FINNVASC and modified PREVENT scores</article-title><source>J. Vasc. Surg.</source><year>2013</year><volume>57</volume><fpage>1</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2012.04.074</pub-id><pub-id pub-id-type="pmid">23040797</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Moxey, P. W. et al. The BASIL survival prediction model in patients with peripheral arterial disease undergoing revascularization in a university hospital setting and comparison with the FINNVASC and modified PREVENT scores. <italic toggle="yes">J. Vasc. Surg.</italic><bold>57</bold>, 1&#8211;7. 10.1016/j.jvs.2012.04.074 (2013).<pub-id pub-id-type="pmid">23040797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2012.04.074</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>P Simons</surname><given-names>J</given-names></name><etal/></person-group><article-title>Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization</article-title><source>J. Vasc. Surg.</source><year>2019</year><volume>69</volume><issue>Suppl</issue><fpage>137S</fpage><lpage>151Se3</lpage><pub-id pub-id-type="doi">10.1016/j.jvs.2018.08.169</pub-id><pub-id pub-id-type="pmid">30497863</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">P Simons, J. et al. Survival prediction in patients with chronic limb-threatening ischemia who undergo infrainguinal revascularization. <italic toggle="yes">J. Vasc. Surg.</italic><bold>69</bold> (Suppl), 137S&#8211;151Se3. 10.1016/j.jvs.2018.08.169 (2019).<pub-id pub-id-type="pmid">30497863</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jvs.2018.08.169</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Takeji</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Impact of frailty on clinical outcomes in patients with critical limb ischemia</article-title><source>Circ. Cardiovasc. Interv</source><year>2018</year><volume>11</volume><fpage>e006778</fpage><pub-id pub-id-type="doi">10.1161/CIRCINTERVENTIONS.118.006778</pub-id><pub-id pub-id-type="pmid">30006333</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Takeji, Y. et al. Impact of frailty on clinical outcomes in patients with critical limb ischemia. <italic toggle="yes">Circ. Cardiovasc. Interv</italic>. <bold>11</bold>, e006778. 10.1161/CIRCINTERVENTIONS.118.006778 (2018).<pub-id pub-id-type="pmid">30006333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCINTERVENTIONS.118.006778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraiss</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Frailty assessment in vascular surgery and its utility in preoperative decision making</article-title><source>Semin Vasc. Surg.</source><year>2015</year><volume>28</volume><fpage>141</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1053/j.semvascsurg.2015.10.003</pub-id><pub-id pub-id-type="pmid">26655058</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kraiss, L. W. et al. Frailty assessment in vascular surgery and its utility in preoperative decision making. <italic toggle="yes">Semin Vasc. Surg.</italic><bold>28</bold>, 141&#8211;147. 10.1053/j.semvascsurg.2015.10.003 (2015).<pub-id pub-id-type="pmid">26655058</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/j.semvascsurg.2015.10.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mehler</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes</article-title><source>Circulation</source><year>2003</year><volume>107</volume><fpage>753</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1161/01.cir.0000049640.46039.52</pub-id><pub-id pub-id-type="pmid">12578880</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Mehler, P. S. et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. <italic toggle="yes">Circulation</italic><bold>107</bold>, 753&#8211;756. 10.1161/01.cir.0000049640.46039.52 (2003).<pub-id pub-id-type="pmid">12578880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/01.cir.0000049640.46039.52</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoga</surname><given-names>NK</given-names></name><etal/></person-group><article-title>Association of blood pressure measurements with peripheral artery disease events</article-title><source>Circulation</source><year>2018</year><volume>138</volume><fpage>1805</fpage><lpage>1814</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.033348</pub-id><pub-id pub-id-type="pmid">29930023</pub-id><pub-id pub-id-type="pmcid">PMC6202170</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Itoga, N. K. et al. Association of blood pressure measurements with peripheral artery disease events. <italic toggle="yes">Circulation</italic><bold>138</bold>, 1805&#8211;1814. 10.1161/CIRCULATIONAHA.118.033348 (2018).<pub-id pub-id-type="pmid">29930023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.118.033348</pub-id><pub-id pub-id-type="pmcid">PMC6202170</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emanuelsson</surname><given-names>F</given-names></name><etal/></person-group><article-title>Impact of LDL cholesterol on microvascular versus macrovascular disease: a Mendelian randomization study</article-title><source>J. Am. Coll. Cardiol.</source><year>2019</year><volume>74</volume><fpage>1465</fpage><lpage>1476</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.07.037</pub-id><pub-id pub-id-type="pmid">31514949</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Emanuelsson, F. et al. Impact of LDL cholesterol on microvascular versus macrovascular disease: a Mendelian randomization study. <italic toggle="yes">J. Am. Coll. Cardiol.</italic><bold>74</bold>, 1465&#8211;1476. 10.1016/j.jacc.2019.07.037 (2019).<pub-id pub-id-type="pmid">31514949</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2019.07.037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujiwara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study</article-title><source>Atherosclerosis</source><year>2004</year><volume>177</volume><fpage>83</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2004.05.028</pub-id><pub-id pub-id-type="pmid">15488869</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Fujiwara, T. et al. Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. <italic toggle="yes">Atherosclerosis</italic><bold>177</bold>, 83&#8211;88. 10.1016/j.atherosclerosis.2004.05.028 (2004).<pub-id pub-id-type="pmid">15488869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.atherosclerosis.2004.05.028</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ohnishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: the Kyushu and Okinawa population study (KOPS)</article-title><source>J. Atheroscler. Thromb.</source><year>2010</year><volume>17</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.5551/jat.3731</pub-id><pub-id pub-id-type="pmid">20523009</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Ohnishi, H. et al. Risk factors for and the prevalence of peripheral arterial disease and its relationship to carotid atherosclerosis: the Kyushu and Okinawa population study (KOPS). <italic toggle="yes">J. Atheroscler. Thromb.</italic><bold>17</bold>, 751&#8211;758. 10.5551/jat.3731 (2010).<pub-id pub-id-type="pmid">20523009</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5551/jat.3731</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Management of hypertriglyceridemia: common questions and answers</article-title><source>Am. Fam. Phys.</source><year>2020</year><volume>102</volume><fpage>347</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">32931217</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Oh, R. C. et al. Management of hypertriglyceridemia: common questions and answers. <italic toggle="yes">Am. Fam. Phys.</italic><bold>102</bold>, 347&#8211;354 (2020).<pub-id pub-id-type="pmid">32931217</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Eraso, L. H. et al. Peripheral arterial dis ease, prevalence and cumulative risk factor profile analysis. <italic toggle="yes">Eur. J. Prev. Cardiol.</italic>. 21: 704&#8211;711. 10.1177/2047487312452968 (2014). (Epub 2012 Jun 27)<pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2047487312452968</pub-id><pub-id pub-id-type="pmcid">PMC4436703</pub-id><pub-id pub-id-type="pmid">22739687</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sigvant</surname><given-names>B</given-names></name><name name-style="western"><surname>Lundin</surname><given-names>F</given-names></name><name name-style="western"><surname>Wahlberg</surname><given-names>E</given-names></name></person-group><article-title>The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral Arte Rial disease</article-title><source>Eur. J. Vasc. Endovasc. Surg.</source><year>2016</year><volume>51</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1016/j.ejvs.2015.10.022</pub-id><pub-id pub-id-type="pmid">26777541</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Sigvant, B., Lundin, F. &amp; Wahlberg, E. The risk of disease progression in peripheral arterial disease is higher than expected: a meta-analysis of mortality and disease progression in peripheral Arte Rial disease. <italic toggle="yes">Eur. J. Vasc. Endovasc. Surg.</italic><bold>51</bold>, 395&#8211;403 (2016). 10.1016/j.ejvs.2015.10.022 (Epub 2016 Jan 6).<pub-id pub-id-type="pmid">26777541</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ejvs.2015.10.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>DL</given-names></name><etal/></person-group><article-title>REACH registry investiga Tors. International prevalence, recognition, and treatment of cardio vascular risk factors in outpatients with atherothrombosis</article-title><source>JAMA</source><year>2006</year><volume>295</volume><fpage>180</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1001/jama.295.2.180</pub-id><pub-id pub-id-type="pmid">16403930</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Bhatt, D. L. et al. REACH registry investiga Tors. International prevalence, recognition, and treatment of cardio vascular risk factors in outpatients with atherothrombosis. <italic toggle="yes">JAMA</italic><bold>295</bold>, 180&#8211;189 (2006). 10.1001/jama.295.2.180.<pub-id pub-id-type="pmid">16403930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.295.2.180</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><mixed-citation publication-type="other">Pande, R. L. et al. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. <italic toggle="yes">Circulation</italic><bold>124</bold>, 17&#8211;23 (2011). 10.1161/CIRCULATIONAHA.110.003954 (Epub 2011 Jun 20).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCULATIONAHA.110.003954</pub-id><pub-id pub-id-type="pmcid">PMC3139992</pub-id><pub-id pub-id-type="pmid">21690489</pub-id></mixed-citation></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Welten</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease</article-title><source>J. Am. Coll. Cardiol.</source><year>2008</year><volume>51</volume><fpage>1588</fpage><lpage>1596</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2007.11.077</pub-id><pub-id pub-id-type="pmid">18420103</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Welten, G. M. et al. Long-term prognosis of patients with peripheral arterial disease: a comparison in patients with coronary artery disease. <italic toggle="yes">J. Am. Coll. Cardiol.</italic><bold>51</bold>, 1588&#8211;1596 (2008). 10.1016/j.jacc.2007.11.077.<pub-id pub-id-type="pmid">18420103</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jacc.2007.11.077</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Non-coronary atherosclero Sis</article-title><source>Eur. Heart J.</source><year>2014</year><volume>35</volume><fpage>1112</fpage><lpage>1119</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu071</pub-id><pub-id pub-id-type="pmid">24595865</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Gallino, A. et al. Non-coronary atherosclero Sis. <italic toggle="yes">Eur. Heart J.</italic><bold>35</bold>, 1112&#8211;1119 (2014). 10.1093/eurheartj/ehu071. Epub 2014 Mar 3.<pub-id pub-id-type="pmid">24595865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/eurheartj/ehu071</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wicke</surname><given-names>FS</given-names></name><etal/></person-group><article-title>Performance of the adapted diabetes complications severity index translated to ICD-10</article-title><source>Am. J. Manag. Care</source><year>2019</year><volume>25</volume><fpage>e45</fpage><lpage>e49</lpage><pub-id pub-id-type="pmid">30763043</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Wicke, F. S. et al. Performance of the adapted diabetes complications severity index translated to ICD-10. <italic toggle="yes">Am. J. Manag Care</italic>. <bold>25</bold>, e45&#8211;e49 (2019).<pub-id pub-id-type="pmid">30763043</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pantalone</surname><given-names>K</given-names></name><etal/></person-group><article-title>Effect of glycemic control on the diabetes complications severity index score and development of complications in people with newly diagnosed type 2 diabetes</article-title><source>J. Diabetes</source><year>2018</year><volume>10</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1111/1753-0407.12613</pub-id><pub-id pub-id-type="pmid">28976724</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Pantalone, K. et al. Effect of glycemic control on the diabetes complications severity index score and development of complications in people with newly diagnosed type 2 diabetes. <italic toggle="yes">J. Diabetes</italic>. <bold>10</bold>, 192&#8211;199 (2018).<pub-id pub-id-type="pmid">28976724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/1753-0407.12613</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><collab>JCS/JSVS</collab></person-group><article-title>Guideline on the management of peripheral arterial disease</article-title><source>Jpn. Circ. J.</source><year>2022</year><volume>25</volume><fpage>25</fpage><lpage>83</lpage></element-citation><mixed-citation id="mc-CR73" publication-type="journal">JCS/JSVS. Guideline on the management of peripheral arterial disease. <italic toggle="yes">Jpn. Circ. J.</italic><bold>25</bold>, 25&#8211;83 (2022).</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>